

Supplementary Figures, Tables and Data

Figure S1




Figure S1: Histogram showing the age range for patients included in the PRAD-TCGA Firehose Legacy cohort used for PCA of RNA-seq expression data.




Figure S2: A Barcode-like representation of PRAD genes comprising the unitary vectors along PC1. Top panel, contains 33 genes identified for a $\delta=0.027$; Lower panel representing 100 genes for a $\delta=0.0235$. Within the barcode the major value (i.e., over-expression) corresponds to PCA3, whereas the lower value (i.e., under-expression) belongs to SEMG1.

Figure S3




Figure S3: Differential expression of PRAD-CES genes in the MSKCC, Cancer Cell 2010 cohort. (A) The oncoprint representation tool from Cbioportal is used. Z scores > 2, normal vs tumor expression values. (B) Frequency of genomic alterations observed in PRAD for PRAD-CES33 genes, a random selected gene list and Pca driver genes. (C) Recurrent somatic and germline mutations for the protein-coding Tumor Protein P63 (TP63) in NSCLC and PRAD. Non-Small Cell Lung Cancer mutations from TRACERx, NEJM & Nature 2017 dataset (n= 447).

Figure S4




Figure S4: Expression analysis of genes from the PRAD-CES using the data cohort of Lapointe et al., 2004.

Figure S5




Figure S5: Expression analysis of genes from the PRAD-CES using the data cohort of Taylor.

Figure S6




Figure S6: Expression analysis of genes from the PRAD-CES using the data cohort of Ross-Adams. Expression analysis of genes from the PRAD-CES using the data cohort of Ross-Adams.

Table S1

| RNAseq-ID' | Ensembl hit | PCA 1 | Gene Name | Description° | Gene type` | Genomic location` (Hurnan,G RCh38.p12) |
|-------------------|--------------------|--------------|------------------|---|--------------------|---|
| 597 | ENSG00000167332 | 0.029 | OR5182 | olfactory receptor family 51 subfamily E member 2 | Protein coding | Chromosome 11: 4,680,171-4,697,854 reverse strand |
| 679 | ENSG00000232806 | 0.032 | AP001610.2 | novel transcript | lincRNA | Chromosome 21:41,559,125-41,562,958 reverse strand. |
| 1070 | ENSG00000159263 | nom | sIM2 | SIM bHLH transcription factor 2 | Protein coding | Chromosome 21: 36,699,133-36,749,917 forward strand. |
| 12766 | ENSG00000159251 | -0.036 | ACTC1 | actin | Protein coding | Chromosome 15: 34,788,095-34,795,726 reverse strand. |
| 1346 | ENSG00000254988 | 0.03 | AP002498.1 | novel transcript | antisense | Chromosome 11: 76,955A17-76,978,619 reverse strand. |
| 3409 | ENSG00000273179 | 0.03 | AC092535.4 | novel transcript | antisense to SPON2 | Chromosome 4: 1,167,778-1,168,174 forward strand. |
| 5302 | ENSG00000105707 | 0.029 | HPN | hepsin | Protein coding | Chromosome 19: 35,040,506-35,066,571 forward strand. |
| 6083 | ENSG00000164175 | 0.028 | SLC45A2 | solute carrier family 45 member 2 | Protein coding | Chromosome 5: 33,944,623-33,984,693 reverse strand. |
| 6202 | ENSG00000095627 | 0.03 | TDRD1 | tudor domain containing 1 | Protein coding | Chromosome 10:114,179,270-114,232,304 forward strand. |

| | | | | | | |
|-------|-----------------|--------|----------|--|----------------|---|
| 10230 | ENSG00000225937 | 0.046 | PCA3 | prostate cancer associated 3 | Antisense | Chromosome 9: 76,691,980-76,863,307 forward strand. |
| 19073 | ENSG00000211689 | 0.029 | TRGC1 | T cell receptor gamma constant 1 | TR C gene | Chromosome 7: 38,257,879-38,265,678 reverse strand. |
| 20094 | ENSG00000280623 | 0.033 | PCAT14 | prostate cancer associated transcript 14 | lincRNA | Chromosome 22: 23,536,881-23,547,797 forward strand. |
| 21927 | ENSG00000242110 | 0.032 | AMACR | alpha-methylacyl-CoA racemase androgen receptor regulated long noncoding RNA | Protein coding | Chromosome 5: 33,986,165-34,008,104 reverse strand. |
| 25811 | ENSG00000260896 | 0.033 | ARLNC1 | 1 | lincRNA | Chromosome 16: 80,826,074-80,892,682 reverse strand. |
| 26265 | ENSG00000144355 | 0.047 | DLX1 | distal-less homeobox 1 | Protein coding | Chromosome 2: 172,084,740-172,089,677 forward strand. |
| 29441 | ENSG00000134184 | -0.031 | GSTM1 | glutathione S-transferase mu 1 | protein coding | Chromosome 1: 109,687,814-109,709,039 forward strand. |
| 29880 | ENSG00000188488 | -0.033 | SERPINA5 | serpin family A member 5 | protein coding | Chromosome 14:94,561,442-94,593,118 forward strand. |
| 30916 | ENSG00000198353 | 0.028 | HOXC4 | homeobox C4 | protein coding | Chromosome 12: 54,016,931-54,056,030 forward strand. |

| | | | | | | |
|-------|---------------------|--------|------------|-------------------------------------|----------------------|---|
| 31604 | ENSG0000105664 | 0.031 | COMP | cartilage oligomeric matrix protein | protein coding | Chromosome 19: 18,782,773-18,791,305 reverse strand. |
| 38412 | ENSG00001065794 | -0.033 | SLC39A2 | solute carrier family 39 member 2 | protein coding | Chromosome 14: 20,999,255-21,001,871 forward strand. |
| 44850 | ENSG00000274326 | 0.035 | AL359314.1 | RNA gene | mist RNA | Chromosome 9: 76,779,657-76,779,917 forward strand. |
| 47198 | ENSG00001024233 | -0.052 | SEMG1 | semenogelin 1 | protein coding | Chromosome 20: 45,207,033-45,209,768 forward strand. |
| 51014 | ENSG00000242899 | 0.035 | RPL7P16 | ribosomal protein L7 pseudogene 16 | Processed pseudogene | Chromosome 3: 132,243,528-132,244,265 reverse strand. |
| 52309 | ENSG00000223400 | 0.036 | AP006748.1 | novel transcript | lincRNA | Chromosome 21:41,576,135-41,581,319 reverse strand. |
| 52910 | ENSG00001024157 | -0.041 | SEMG2 | semenogelin 2 | Protein coding | Chromosome 20: 45,221,300-45,224,458 forward strand. |
| 59397 | ENSG000010197757 | 0.034 | HOXC6 | homeobox C6 | Protein coding | Chromosome 12:53,990,624-54,030,823 forward strand |
| 11041 | ENSG000010176153.11 | -0.028 | GPX2 | Glutathione Peroxidase 2 | Protein coding | Chromosome 14: 64,939,152-64,942,905 reverse strand. |

| | | | | | | |
|---|--------------------|--------|------------|------------------------------------|----------------|---|
| 23459 | ENSG00000250767.1 | 0.028 | AC139783.1 | Fumarate Hydratase (FH) Pseudogene | lncRNA | Chromosome 5: 33,997,044-33,997,724 reverse strand. |
| 28911 | ENSG00000101443.16 | -0_028 | W11DC2 | WAP Four-Disulfide Core Domain 2 | Protein coding | Chromosome 20: 45,469,753-45,481,532 forward strand |
| 36502 | ENSG00000095713 | -0_027 | CRTAC1 | cartilage acidic protein 1 | protein coding | Chromosome 10: 97,865,000-98,030,828 reverse strand. |
| 38100 | ENSG00000186081 | -11027 | KRT5 | Keratin 5 | Protein coding | Chromosome 12: 52,514,575-52,520,530 reverse strand |
| 4450 | ENSG00000073282 | -0_027 | TP63 | Tumor Protein P63 | Protein coding | Chromosome 3: 189,631,389-189,897,276 forward strand. |
| 53412 | ENSG00000211695 | 0.027 | TRGV9 | T cell receptor gamma variable 9 | TR V gene | Chromosome 7: 38,317,017-38,318,861 reverse strand. |
| Legend: a PRAD-TCGA; b Genecards; c Ensembl | | | | | | |

Table SI: Detailed information about the 33 genes included in the PRAD core signature (PRAD-CES33).

| <u>PRAD-TCGA</u> I | <u>Genecards</u> | <u>Ensembl</u> | <u>Text-mining</u> | | | | <u>Genecards</u> | <u>Gene Product Expression'</u> | | |
|-----------------------|------------------|----------------|--------------------|----------------------------------|----------------------------|------------------------|---|---------------------------------|----------------------|---------------------|
| | | | <u>Association</u> | <u>Driver ; Biomarker; Other</u> | <u>Disease Association</u> | <u>URL</u> | | <u>Prostate</u> | <u>Other tissues</u> | <u>Localization</u> |
| 597 | OR51E2 | Protein coding | YES | over-expression | D;B;ND | MalaCards: No disorder | bin/carddisp.pl?gene=OR51E2&keywords=ORMn...//www.ye. | ND | ND | PM |

| | | | | | | | | | | |
|---------------|--------------------|-----------------------------------|-----|-------------------------|------------------|--|---|-----|-----|--------------------------|
| | | | | | | ers were found for OR51E 2 Gene | | | | |
| 67 9 | AP0 016 10.2 | linc RNA | ND | ND | ND;N D;ND | MalaC ards: No data availab le. | bin/carddisp.pl?gene=ENSG00000232806&keywords=AP001610 | YES | >10 | ND |
| 10 70 | SIM 2 | Prot ein codi ng | YES | over- expre ssion | D?; NO:N D | MalaC ards: down syndro me. | bin/carddisp.pl?gene=SIM2&keywords=SIM2 | ND | 2 | IC, nucl eus |
| 12 76 6 | ACT C1 | Prot ein codi ng | ND | ND | ND;N D;ND | MalaC ards: 94 diseas es, no prostat e cancer, 2 other tumors . | bin/carddisp.pl?gene=ACTC1&keywords=ACTC1 | ND | 5 | IC, cyto plas m |
| 13 46 | AP0 024 98.1 | anti sens e | ND | ND | ND;N D;ND | MalaC ards: No data availab le. | bin/carddisp.pl?gene=ENSG000002731796&keywords=AC092535 | YES | >10 | ND |
| 34 09 | AC0 925 35.4 | anti sens e to SPO N2 | ND | ND | ND;N D;ND | MalaC ards: No data availab le. | https://www.genecards.org/cgi- | ND | ND | ND |
| 53 02 | HPN | Prot ein codi ng | YES | over- expre ssion | D;B;N D | Male cards: prostat e cancer 1. | bin/carddisp.pl?gene=1-1PN&keywords=HPN | YES | >10 | EC |

| | | | | | | | | | | |
|-------|---------|----------------|-----|----------------------------------|----------|--|--|-----|-----|---------------------|
| 6083 | SLC45A2 | Protein coding | YES | ND | D?;B;ND | (melanome). | bin/carddisp.pl?gene=SLC45A2&keywords=S https://www.genecards.org/cgi- | NO | 3 | PM |
| 6202 | TDRD1 | Protein coding | YES | over-expression | D?;B;ND | MalaCards: No disorders were found for TDRD1 Gene. | bin/carddisp.pl?gene=TDRD1&keywords=TD | ND | 5 | IC, nucleus |
| 10230 | PCA3 | Antisense | YES | over-expression | D;B;ND | MalaCards: 7 diseases, none cancer. | bin/carddisp.pl?gene=PCA3&keywords=PCA3 | YES | >10 | EC (low confidence) |
| 19073 | TRGC1 | TRC gene | YES | over-expression | ND;ND;ND | TRGC1 Gene. | bin/carddisp.pl?gene=TRGC16keywords=TR | ND | ND | ND |
| 20094 | PCAT14 | lincRNA | YES | down regulation over-expression, | D;B;ND | MalaCards: No data available. | https://www.genecards.org/cgi- | ND | ND | ND |
| 21927 | AMACR | Protein coding | YES | polymorphism | D;B;ND | cancer, | bin/carddisp.pl?gene=PCAT14&keywords=PC | YES | >10 | IC, cytoplasm |
| 25811 | ARLNC1 | lincRNA | YES | over-expression | D;ND;ND | MalaCards: No data available. | napswwww.genecardos.orwcgi- | ND | ND | ND |
| 26265 | DLX1 | Protein coding | YES | over-expression down regulation, | D;B;ND | MalaCards: 4 diseases, none cancer. | bin/carddisp.pl?gene=AMACR&keywords=AM | ND | 4 | IC, nucleus |
| 29441 | GSTM1 | protein coding | YES | polymorphism | ND;ND;ND | cancer. | hdps://www.genecards.org/egi- | YES | >10 | EC, IC |

| | | | | | | | | | | |
|-------|------------|----------------------|----------|-----------------|-----------|--------------------------------------|---|-----|-----|-------------|
| 29880 | SERPINA5 | protein coding | YES | down regulation | 0?;ND:ND | MalaCards: No data available. | bin/carddisp.pl?gene=ARLNC1&keywords=ARLNC1 | YES | >10 | EC |
| 30916 | HOXC4 | protein coding | YES | overexpression | D?;NID:ND | MalaCards: 36 diseases, none cancer. | https://www.genecards.org/cgi- | ND | ND | IC, nucleus |
| 31604 | COMP | protein coding | ND | overexpression | D?;B;ND | MalaCards: No data available. | bin/carddisp.pl?gene=DLX1&keywords=DLX1 | YES | >10 | EC |
| 38412 | SLC39A2 | protein coding | YES | down regulation | D?;ND;ND | MalaCards: No data available. | bin/carddisp.pl?gene=GSTM1&keywords=GSTM1 | ND | ND | PM |
| 44850 | AL359314.1 | miRNA | Putative | ND | ND;ND;ND | MalaCards: No data available. | bin/carddisp.pl?gene=SEBPrNA5&keywords=SEBPrNA5 | ND | ND | ND |
| 47198 | SEM1G1 | protein coding | YES | ND | ND;B;ND | MalaCards: No data available. | rrepe.www.yerrecerU b.-7,1,1,1- | YES | >10 | EC |
| 51014 | RPL7P16 | Processed pseudogene | ND | ND | ND;ND;ND | MalaCards: No data available. | bin/carddisp.pl?gene=HOXC4&keywords=HOXC4 | YES | ND | IC |
| 52309 | AP006748.1 | lincRNA | ? | ND | ND;ND;ND | MalaCards: No data available. | irrye.www.yer mud: ue.urytLyr- | YES | ND | IC, EC |

| | | | | | | | | | | |
|-------|------------|----------------|-----|----------------|-------------|---|---|-----|------------------------|--------|
| 52910 | SEM G2 | Protein coding | YES | ND | NOB; ND | esophagus. | bin/carddisp.pl?gene=COMP&keywords=COMP | YES | EC | ND |
| 59397 | HOXC6 | Protein coding | YES | overexpression | D;B;ND | MalaCards: No data available. | hdps://www.genecards.org/cg, | ND | 1 | EC |
| 11041 | GPX2 | Protein coding | YES | overexpression | D?:13: NOA? | MalaCards: No data available | bin/carddisp.pl?gene=SLC39A2&keywords=SLC39A2 | YES | >10 | EC, PM |
| 23459 | ACL39783 I | lncRNA | ND | ND | ND;ND | including prostate. | bin/carddisp.pl?gene=ENSG000002743268Eeg="1=-,,, | YES | >10 | ND |
| 28911 | WFDC2 | Protein coding | NO | overexpression | D?;B;ND | MalaCards: 97 diseases cervical cancer, hem | bin/carddisp.pl?gene=SEMG16keywords=SE | NO | >10 | |
| 36502 | CRTAC1 | protein coding | ND | ND | ND;ND | MalaCards: No disorders were found for TRG' | https://www.genecards.org/cgi- | YES | >10 | |
| 38100 | KRT5 | Protein coding | YES | ND | ND;ND | MalaCards: colon cancer, barren | bin/carddisp.pl?gene=RPL7P16&keywords=R https://www.genecards.org/cgi- | 5 | IC, PM, EC | |
| 4450 | TP63 | Protein coding | YES | downregulation | D?;B;ND | MalaCards: Ovarian cancer. | bin/carddisp.pl?gene=ENSG000002234008Ee | > 5 | IC, cytoplasm, nucleus | |

| | | | | | | | | | | |
|---|-------|-----------|----|----|-------|-------------------------------------|---|----|------|----|
| | | | | | | | | | , EC | |
| 53412 | TRGV9 | TR V gene | NO | ND | ND;ND | MalaCards:181 diseases, some cancer | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SEMG2&keywords=SE | ND | ND | ND |
| <p>Legend: D, Driver; D?, Putative driver; B, Biomarker; NOA, Non-Oncogen Addiction; ND, No Data ; aIntegrated Proteomics or The Human Protein Atlas or RNA-gene expression; EC, Extracellular; IC, Intracellular; PM, Plasma Membrane; ?, Ambiguos info.</p> | | | | | | | | | | |

Table SII: Gene Classification, Disease Association and Gene Product Expression

Table S3

| Gene Name | Dataset | | | Up vs. Down* |
|---|----------|------------|--------|--------------|
| | Lapointe | Ross-Adams | Taylor | |
| ORE51E2 | √ | √ | √ | Up |
| SIM2 | √ | √ | √ | Up |
| ACTC1 | 0 | √ | √ | Down |
| HPN | √ | √ | √ | Up |
| SLC45A2 | √ | √ | √ | Up |
| TDRD1 | 0 | √ | √ | Up |
| AMARC | √ | √ | √ | Up |
| DLX1 | 0 | √ | √ | Up |
| GSTM1 | 0 | √ | X | Down |
| SERPINA5 | √ | √ | X | Down |
| HOXC4 | √ | √ | √ | Up |
| HOXC6 | 0 | √ | 0 | Up |
| COMP | X | √ | X | Up |
| SLC39A2 | √ | √ | X | Down |
| SEMG1 | X | X | X | n.s |
| SEMG2 | X | X | X | n.s |
| GPX2 | √ | √ | √ | Down |
| PCA3 | √ | √ | 0 | Up |
| WFDC2 | √ | √ | √ | Down |
| <p>Legend: "√": Significant difference in expression between benign and primary tumors at P<0.05; "X": no significant difference; "0": not available; * Consistent Up vs. Down-regulation in primary tumors vs. benign.</p> | | | | |

Table SIII: Summary of the expression of PRAD-CES genes in three independent data cohorts.

Data S1

| | |
|----------------------------|--|
| Data S1 | Enrichment analysis for Biological Process using the tool Enrich |
| GO_Biological_Process_2018 | |
| Tab Content: | |
| Tab 1 | PC1 |
| Tab 2 | PC2 |
| Tab 3 | PC3 |

| Term | Overlap | P-value | Adjusted P-value | Old P-value | Old Adjusted P-value | Odds Ratio | Combined Score | Genes |
|--|---------|----------|------------------|-------------|----------------------|------------|----------------|----------------------------------|
| regulation of serine-type endopeptidase activity (GO:1900003) | 11-Feb | 1.44E-04 | 0.734104 | 0 | 0 | 110.1928 | 974.8417 | SEMG2; SEMG1 |
| positive regulation of endopeptidase activity (GO:0010950) | 24-Feb | 7.12E-04 | 1 | 0 | 0 | 50.50505 | 366.0117 | SEMG2; SEMG1 |
| antibacterial humoral response (GO:0019731) | Feb-35 | 0.00152 | 1 | 0 | 0 | 34.63203 | 224.76923 | SEMG2; SEMG1 |
| spermatogenesis (GO:0007283) | 3/153 | 0.00202 | 1 | 0 | 0 | 11.88354 | 73.709714 | TDRD1; WFDC2; SERPIN A5 |
| male gamete generation (GO:0048232) | 3/154 | 0.00206 | 1 | 0 | 0 | 11.80638 | 73.012031 | TDRD1; WFDC2; SERPIN A5 |
| protein heterooligomerization (GO:0051291) | Feb-49 | 0.00296 | 1 | 0 | 0 | 24.73717 | 144.05238 | SEMG2; SEMG1 |
| positive regulation of blood pressure (GO:0045777) | 06-Jan | 0.00986 | 1 | 0 | 0 | 101.0101 | 466.58897 | OR51E2 |
| positive regulation of fibroblast apoptotic process (GO:2000271) | 06-Jan | 0.00986 | 1 | 0 | 0 | 101.0101 | 466.58897 | TP63 |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|----------|
| positive regulation of hormone metabolic process (GO:0032352) | 06-Jan | 0.00986 | 1 | 0 | 0 | 101.0101 | 466.58897 | HPN |
| negative regulation of calcium ion import (GO:0090281) | 07-Jan | 0.01149 | 1 | 0 | 0 | 86.58009 | 386.65618 | SEMG1 |
| xenobiotic catabolic process (GO:0042178) | 07-Jan | 0.01149 | 1 | 0 | 0 | 86.58009 | 386.65618 | GSTM1 |
| basement membrane organization (GO:0071711) | 08-Jan | 0.01313 | 1 | 0 | 0 | 75.75758 | 328.26865 | HPN |
| regulation of fibroblast apoptotic process (GO:2000269) | 08-Jan | 0.01313 | 1 | 0 | 0 | 75.75758 | 328.26865 | TP63 |
| detection of mechanical stimulus involved in sensory perception (GO:0050974) | 09-Jan | 0.01476 | 1 | 0 | 0 | 67.34007 | 283.91662 | HPN |
| regulation of flagellated sperm motility (GO:1901317) | 09-Jan | 0.01476 | 1 | 0 | 0 | 67.34007 | 283.91662 | SEMG1 |
| positive regulation of developmental process (GO:0051094) | 2/113 | 0.0149 | 1 | 0 | 0 | 10.72674 | 45.118067 | DLX1;HPN |
| mitotic G1/S transition checkpoint (GO:0044819) | 10-Jan | 0.01638 | 1 | 0 | 0 | 60.60606 | 249.18786 | TP63 |
| skeletal muscle thin filament assembly (GO:0030240) | 10-Jan | 0.01638 | 1 | 0 | 0 | 60.60606 | 249.18786 | ACTC1 |
| mitotic G1 DNA damage checkpoint (GO:0031571) | 10-Jan | 0.01638 | 1 | 0 | 0 | 60.60606 | 249.18786 | TP63 |
| G1 DNA damage checkpoint (GO:0044783) | 10-Jan | 0.01638 | 1 | 0 | 0 | 60.60606 | 249.18786 | TP63 |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|--------|
| regulation of plasminogen activation (GO:0010755) | 10-Jan | 0.01638 | 1 | 0 | 0 | 60.60606 | 249.18786 | HPN |
| heart process (GO:0003015) | 11-Jan | 0.01801 | 1 | 0 | 0 | 55.09642 | 221.32716 | ACTC1 |
| cochlea morphogenesis (GO:0090103) | 11-Jan | 0.01801 | 1 | 0 | 0 | 55.09642 | 221.32716 | HPN |
| hemidesmosome assembly (GO:0031581) | 11-Jan | 0.01801 | 1 | 0 | 0 | 55.09642 | 221.32716 | KRT5 |
| hepatocyte growth factor receptor signaling pathway (GO:0048012) | 11-Jan | 0.01801 | 1 | 0 | 0 | 55.09642 | 221.32716 | HPN |
| cell-substrate junction assembly (GO:0007044) | 11-Jan | 0.01801 | 1 | 0 | 0 | 55.09642 | 221.32716 | KRT5 |
| response to thyroid hormone (GO:0097066) | 11-Jan | 0.01801 | 1 | 0 | 0 | 55.09642 | 221.32716 | HPN |
| skeletal myofibril assembly (GO:0014866) | 12-Jan | 0.01963 | 1 | 0 | 0 | 50.50505 | 198.52902 | ACTC1 |
| cellular response to fatty acid (GO:0071398) | 12-Jan | 0.01963 | 1 | 0 | 0 | 50.50505 | 198.52902 | OR51E2 |
| response to fatty acid (GO:0070542) | 13-Jan | 0.02125 | 1 | 0 | 0 | 46.62005 | 179.56317 | OR51E2 |
| DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator (GO:0006978) | 13-Jan | 0.02125 | 1 | 0 | 0 | 46.62005 | 179.56317 | TP63 |
| DNA damage response, signal transduction resulting in transcription (GO:0042772) | 14-Jan | 0.02286 | 1 | 0 | 0 | 43.29004 | 163.56363 | TP63 |
| response to X-ray (GO:0010165) | 15-Jan | 0.02447 | 1 | 0 | 0 | 40.40404 | 149.90403 | TP63 |
| regulation of water loss via skin (GO:0033561) | 16-Jan | 0.02609 | 1 | 0 | 0 | 37.87879 | 138.12059 | TP63 |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|-----------------|
| establishment of skin barrier (GO:0061436) | 16-Jan | 0.02609 | 1 | 0 | 0 | 37.87879 | 138.12059 | TP63 |
| positive regulation of protein processing (GO:0010954) | 17-Jan | 0.02769 | 1 | 0 | 0 | 35.65062 | 127.86297 | HPN |
| cardiac myofibril assembly (GO:0055003) | 17-Jan | 0.02769 | 1 | 0 | 0 | 35.65062 | 127.86297 | ACTC1 |
| positive regulation by host of viral transcription (GO:0043923) | 17-Jan | 0.02769 | 1 | 0 | 0 | 35.65062 | 127.86297 | HPN |
| positive regulation of nitrogen compound metabolic process (GO:0051173) | 17-Jan | 0.02769 | 1 | 0 | 0 | 35.65062 | 127.86297 | HPN |
| negative regulation of programmed cell death (GO:0043069) | 3/408 | 0.02925 | 1 | 0 | 0 | 4.456328 | 15.738604 | COMP; HPN; TP63 |
| piRNA metabolic process (GO:0034587) | 18-Jan | 0.0293 | 1 | 0 | 0 | 33.67003 | 118.86179 | TDRD1 |
| regulation of cellular response to transforming growth factor beta stimulus (GO:1903844) | 18-Jan | 0.0293 | 1 | 0 | 0 | 33.67003 | 118.86179 | DLX1 |
| muscle tissue morphogenesis (GO:0060415) | 19-Jan | 0.0309 | 1 | 0 | 0 | 31.89793 | 110.9067 | ACTC1 |
| negative regulation of calcium ion transport (GO:0051926) | 19-Jan | 0.0309 | 1 | 0 | 0 | 31.89793 | 110.9067 | SEMG1 |
| steroid hormone mediated signaling pathway (GO:0043401) | 20-Jan | 0.0325 | 1 | 0 | 0 | 30.30303 | 103.83117 | OR51E2 |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|-----------|
| intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771) | 20-Jan | 0.0325 | 1 | 0 | 0 | 30.30303 | 103.83117 | TP63 |
| cellular response to steroid hormone stimulus (GO:0071383) | 20-Jan | 0.0325 | 1 | 0 | 0 | 30.30303 | 103.83117 | OR51E2 |
| zinc II ion transport (GO:0006829) | 21-Jan | 0.0341 | 1 | 0 | 0 | 28.86003 | 97.501733 | SLC39A2 |
| glutathione derivative metabolic process (GO:1901685) | 22-Jan | 0.0357 | 1 | 0 | 0 | 27.54821 | 91.810234 | GSTM1 |
| glutathione derivative biosynthetic process (GO:1901687) | 22-Jan | 0.0357 | 1 | 0 | 0 | 27.54821 | 91.810234 | GSTM1 |
| regulation of calcium ion import (GO:0090279) | 22-Jan | 0.0357 | 1 | 0 | 0 | 27.54821 | 91.810234 | SEMG1 |
| inner ear morphogenesis (GO:0042472) | 22-Jan | 0.0357 | 1 | 0 | 0 | 27.54821 | 91.810234 | HPN |
| zinc II ion transmembrane transport (GO:0071577) | 23-Jan | 0.03729 | 1 | 0 | 0 | 26.35046 | 86.668143 | SLC39A2 |
| positive regulation of blood circulation (GO:1903524) | 23-Jan | 0.03729 | 1 | 0 | 0 | 26.35046 | 86.668143 | OR51E2 |
| limb development (GO:0060173) | 24-Jan | 0.03888 | 1 | 0 | 0 | 25.25253 | 82.002337 | COMP |
| negative regulation of epithelial to mesenchymal transition (GO:0010719) | 25-Jan | 0.04047 | 1 | 0 | 0 | 24.24242 | 77.751915 | HPN |
| positive regulation of cell differentiation (GO:0045597) | 2/194 | 0.0406 | 1 | 0 | 0 | 6.248047 | 20.018813 | DLX1;TP63 |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|------------------------|
| response to gamma radiation (GO:0010332) | 26-Jan | 0.04205 | 1 | 0 | 0 | 23.31002 | 73.86577 | TP63 |
| negative regulation of catalytic activity (GO:0043086) | 26-Jan | 0.04205 | 1 | 0 | 0 | 23.31002 | 73.86577 | SERPINA5 |
| cardiac muscle cell development (GO:0055013) | 27-Jan | 0.04363 | 1 | 0 | 0 | 22.44669 | 70.300713 | ACTC1 |
| transition metal ion transport (GO:0000041) | 27-Jan | 0.04363 | 1 | 0 | 0 | 22.44669 | 70.300713 | SLC39A2 |
| modulation by host of viral transcription (GO:0043921) | 27-Jan | 0.04363 | 1 | 0 | 0 | 22.44669 | 70.300713 | HPN |
| negative regulation of apoptotic process (GO:0043066) | 3/485 | 0.04518 | 1 | 0 | 0 | 3.748828 | 11.610092 | COMP; HPN; TP63 |
| regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900739) | 30-Jan | 0.04837 | 1 | 0 | 0 | 20.20202 | 61.190341 | TP63 |
| positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900740) | 30-Jan | 0.04837 | 1 | 0 | 0 | 20.20202 | 61.190341 | TP63 |
| positive regulation of transcription from RNA polymerase II promoter (GO:0045944) | 4/848 | 0.04956 | 1 | 0 | 0 | 2.858776 | 8.5891434 | DLX1; HMX4; SIM2; TP63 |
| protein oligomerization (GO:0051259) | 2/217 | 0.04965 | 1 | 0 | 0 | 5.585812 | 16.772506 | SEMG2; SEMG1 |

| | | | | | | | | |
|---|--------|---------|---|---|---|----------|-----------|-----------------|
| negative regulation of BMP signaling pathway (GO:0030514) | Jan-32 | 0.05151 | 1 | 0 | 0 | 18.93939 | 56.173728 | DLX1 |
| positive regulation of Notch signaling pathway (GO:0045747) | Jan-33 | 0.05308 | 1 | 0 | 0 | 18.36547 | 53.920949 | TP63 |
| ncRNA metabolic process (GO:0034660) | Jan-34 | 0.05464 | 1 | 0 | 0 | 17.82531 | 51.817059 | TDRD1 |
| positive regulation of osteoblast differentiation (GO:0045669) | Jan-35 | 0.05621 | 1 | 0 | 0 | 17.31602 | 49.848373 | TP63 |
| cardiac muscle tissue development (GO:0048738) | Jan-36 | 0.05777 | 1 | 0 | 0 | 16.83502 | 48.002805 | ACTC1 |
| cardiac muscle tissue morphogenesis (GO:0055008) | Jan-36 | 0.05777 | 1 | 0 | 0 | 16.83502 | 48.002805 | ACTC1 |
| positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901030) | Jan-37 | 0.05932 | 1 | 0 | 0 | 16.38002 | 46.269637 | TP63 |
| defense response to bacterium (GO:0042742) | 2/241 | 0.0598 | 1 | 0 | 0 | 5.029549 | 14.166762 | SEMG2; SEMG1 |
| actin-myosin filament sliding (GO:0033275) | Jan-38 | 0.06088 | 1 | 0 | 0 | 15.94896 | 44.639341 | ACTC1 |
| muscle filament sliding (GO:0030049) | Jan-38 | 0.06088 | 1 | 0 | 0 | 15.94896 | 44.639341 | ACTC1 |
| mitotic DNA damage checkpoint (GO:0044773) | Jan-39 | 0.06243 | 1 | 0 | 0 | 15.54002 | 43.103412 | TP63 |
| positive regulation of viral transcription (GO:0050434) | Jan-41 | 0.06553 | 1 | 0 | 0 | 14.78197 | 40.285 | HPN |

| | | | | | | | | |
|---|--------|---------|---|---|---|----------|-----------|------------|
| intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332) | Jan-43 | 0.06862 | 1 | 0 | 0 | 14.09443 | 37.762335 | TP63 |
| heart contraction (GO:0060047) | Jan-44 | 0.07016 | 1 | 0 | 0 | 13.7741 | 36.598355 | ACTC1 |
| myofibril assembly (GO:0030239) | Jan-47 | 0.07476 | 1 | 0 | 0 | 12.89491 | 33.442408 | ACTC1 |
| positive regulation of macromolecule metabolic process (GO:0010604) | 2/276 | 0.07575 | 1 | 0 | 0 | 4.391744 | 11.331806 | ACTC1; HPN |
| intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630) | Jan-48 | 0.07629 | 1 | 0 | 0 | 12.62626 | 32.489861 | TP63 |
| glutathione metabolic process (GO:0006749) | Jan-49 | 0.07782 | 1 | 0 | 0 | 12.36858 | 31.581561 | GSTM1 |
| antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844) | Jan-49 | 0.07782 | 1 | 0 | 0 | 12.36858 | 31.581561 | SEMG1 |
| blood circulation (GO:0008015) | Jan-50 | 0.07934 | 1 | 0 | 0 | 12.12121 | 30.71464 | ACTC1 |
| heart morphogenesis (GO:0003007) | Jan-50 | 0.07934 | 1 | 0 | 0 | 12.12121 | 30.71464 | ACTC1 |
| positive regulation of ossification (GO:0045778) | Jan-52 | 0.08239 | 1 | 0 | 0 | 11.65501 | 29.094629 | TP63 |
| proteolysis (GO:0006508) | 2/291 | 0.08297 | 1 | 0 | 0 | 4.165365 | 10.368844 | HPN;W FDC2 |
| negative regulation of cellular response to transforming growth factor beta stimulus (GO:1903845) | Jan-53 | 0.08391 | 1 | 0 | 0 | 11.43511 | 28.336898 | DLX1 |

| | | | | | | | | |
|---|--------|---------|---|---|---|----------|-----------|----------------------------|
| negative regulation of cellular response to growth factor stimulus (GO:0090288) | Jan-55 | 0.08693 | 1 | 0 | 0 | 11.01928 | 26.915718 | DLX1 |
| regulation of BMP signaling pathway (GO:0030510) | Jan-56 | 0.08845 | 1 | 0 | 0 | 10.82251 | 26.248626 | DLX1 |
| protein homotetramerization (GO:0051289) | Jan-57 | 0.08995 | 1 | 0 | 0 | 10.63264 | 25.608331 | TP63 |
| regulation of transcription from RNA polymerase II promoter (GO:0006357) | 5/1478 | 0.09278 | 1 | 0 | 0 | 2.050273 | 4.8746678 | DLX1;HOXC4;SIM2;TP63;HOXC6 |
| negative regulation of peptidase activity (GO:0010466) | Jan-62 | 0.09746 | 1 | 0 | 0 | 9.775171 | 22.7598 | SERPINA5 |
| negative regulation of neuron differentiation (GO:0045665) | Jan-64 | 0.10044 | 1 | 0 | 0 | 9.469697 | 21.762845 | DLX1 |
| regulation of cell division (GO:0051302) | Jan-65 | 0.10193 | 1 | 0 | 0 | 9.324009 | 21.290822 | TP63 |
| cellular response to light stimulus (GO:0071482) | Jan-66 | 0.10342 | 1 | 0 | 0 | 9.182736 | 20.835276 | TP63 |
| negative regulation of epithelial cell proliferation (GO:0050680) | Jan-66 | 0.10342 | 1 | 0 | 0 | 9.182736 | 20.835276 | HPN |
| cellular response to UV (GO:0034644) | Jan-67 | 0.1049 | 1 | 0 | 0 | 9.045681 | 20.395403 | TP63 |
| regulation of endopeptidase activity (GO:0052548) | Jan-68 | 0.10639 | 1 | 0 | 0 | 8.912656 | 19.970451 | SERPINA5 |
| regulation of epithelial to mesenchymal transition (GO:0010717) | Jan-68 | 0.10639 | 1 | 0 | 0 | 8.912656 | 19.970451 | HPN |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|----------------------------------|
| regulation of osteoblast differentiation (GO:0045667) | Jan-69 | 0.10787 | 1 | 0 | 0 | 8.783487 | 19.559715 | TP63 |
| regulation of Notch signaling pathway (GO:0008593) | Jan-70 | 0.10934 | 1 | 0 | 0 | 8.658009 | 19.162531 | TP63 |
| positive regulation of transcription, DNA-templated (GO:0045893) | 4/1120 | 0.11076 | 1 | 0 | 0 | 2.164502 | 4.7626504 | DLX1;H OXC4;SI M2;TP6 3 |
| actomyosin structure organization (GO:0031032) | Jan-71 | 0.11082 | 1 | 0 | 0 | 8.536065 | 18.778277 | ACTC1 |
| positive regulation of growth (GO:0045927) | Jan-71 | 0.11082 | 1 | 0 | 0 | 8.536065 | 18.778277 | HPN |
| regulation of neuron death (GO:1901214) | Jan-72 | 0.11229 | 1 | 0 | 0 | 8.417508 | 18.406364 | TP63 |
| regulation of epithelial cell proliferation (GO:0050678) | Jan-72 | 0.11229 | 1 | 0 | 0 | 8.417508 | 18.406364 | HPN |
| negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090101) | Jan-77 | 0.11962 | 1 | 0 | 0 | 7.870917 | 16.713654 | DLX1 |
| response to ionizing radiation (GO:0010212) | Jan-77 | 0.11962 | 1 | 0 | 0 | 7.870917 | 16.713654 | TP63 |
| extracellular matrix disassembly (GO:0022617) | Jan-78 | 0.12107 | 1 | 0 | 0 | 7.770008 | 16.405225 | HPN |
| regulation of hydrolase activity (GO:0051336) | Jan-80 | 0.12398 | 1 | 0 | 0 | 7.575758 | 15.815198 | SERPIN A5 |
| sensory perception of sound (GO:0007605) | Jan-81 | 0.12543 | 1 | 0 | 0 | 7.48223 | 15.532878 | HPN |

| | | | | | | | | |
|---|--------|---------|---|---|---|----------|-----------|------------------|
| epidermis development (GO:0008544) | Jan-81 | 0.12543 | 1 | 0 | 0 | 7.48223 | 15.532878 | KRT5 |
| positive regulation of protein secretion (GO:0050714) | Jan-82 | 0.12688 | 1 | 0 | 0 | 7.390983 | 15.258568 | OR51E2 |
| DNA damage response, signal transduction by p53 class mediator (GO:0030330) | Jan-82 | 0.12688 | 1 | 0 | 0 | 7.390983 | 15.258568 | TP63 |
| negative regulation of endopeptidase activity (GO:0010951) | Jan-83 | 0.12833 | 1 | 0 | 0 | 7.301935 | 14.991954 | SERPIN A5 |
| positive regulation of gene expression (GO:0010628) | 3/771 | 0.13306 | 1 | 0 | 0 | 2.358212 | 4.7563433 | ACTC1; HPN;TP 63 |
| cellular response to BMP stimulus (GO:0071773) | Jan-87 | 0.13409 | 1 | 0 | 0 | 6.966214 | 13.996649 | DLX1 |
| divalent metal ion transport (GO:0070838) | Jan-88 | 0.13553 | 1 | 0 | 0 | 6.887052 | 13.764287 | SLC39A 2 |
| regulation of neuron apoptotic process (GO:0043523) | Jan-89 | 0.13696 | 1 | 0 | 0 | 6.80967 | 13.538025 | TP63 |
| protein tetramerization (GO:0051262) | Jan-90 | 0.13839 | 1 | 0 | 0 | 6.734007 | 13.317639 | TP63 |
| cellular response to acid chemical (GO:0071229) | Jan-91 | 0.13982 | 1 | 0 | 0 | 6.660007 | 13.102918 | OR51E2 |
| positive regulation of cellular metabolic process (GO:0031325) | Jan-92 | 0.14125 | 1 | 0 | 0 | 6.587615 | 12.893659 | HPN |
| skin development (GO:0043588) | Jan-94 | 0.14409 | 1 | 0 | 0 | 6.447453 | 12.490764 | TP63 |
| positive regulation of protein localization to membrane (GO:1905477) | Jan-95 | 0.14551 | 1 | 0 | 0 | 6.379585 | 12.296767 | TP63 |

| | | | | | | | | |
|--|--------|---------|---|---|---|----------|-----------|-----------------------|
| negative regulation of cell motility (GO:2000146) | Jan-97 | 0.14834 | 1 | 0 | 0 | 6.248047 | 11.922832 | SEMG1 |
| positive regulation of neuron differentiation (GO:0045666) | Jan-98 | 0.14975 | 1 | 0 | 0 | 6.184292 | 11.742579 | DLX1 |
| positive regulation of cell growth (GO:0030307) | Jan-98 | 0.14975 | 1 | 0 | 0 | 6.184292 | 11.742579 | HPN |
| response to UV (GO:0009411) | Jan-98 | 0.14975 | 1 | 0 | 0 | 6.184292 | 11.742579 | TP63 |
| regulation of apoptotic process (GO:0042981) | 3/815 | 0.14989 | 1 | 0 | 0 | 2.230898 | 4.2339671 | COMP; HPN;TP 63 |
| cellular response to transforming growth factor beta stimulus (GO:0071560) | 1/100 | 0.15257 | 1 | 0 | 0 | 6.060606 | 11.394765 | DLX1 |
| peptide metabolic process (GO:0006518) | 1/104 | 0.15818 | 1 | 0 | 0 | 5.827506 | 10.746161 | GSTM1 |
| positive regulation of epithelial cell proliferation (GO:0050679) | 1/107 | 0.16236 | 1 | 0 | 0 | 5.664118 | 10.297057 | HPN |
| negative regulation of hydrolase activity (GO:0051346) | 1/108 | 0.16375 | 1 | 0 | 0 | 5.611672 | 10.153891 | SERPIN A5 |
| positive regulation of establishment of protein localization to mitochondrion (GO:1903749) | 1/110 | 0.16652 | 1 | 0 | 0 | 5.509642 | 9.8767739 | TP63 |
| cellular response to oxidative stress (GO:0034599) | 1/115 | 0.17341 | 1 | 0 | 0 | 5.270092 | 9.2336221 | GPX2 |
| actin filament organization (GO:0007015) | 1/120 | 0.18025 | 1 | 0 | 0 | 5.050505 | 8.6535986 | ACTC1 |
| regulation of cell differentiation (GO:0045595) | 1/121 | 0.18161 | 1 | 0 | 0 | 5.008765 | 8.5444109 | DLX1 |

| | | | | | | | | |
|---|-------|---------|---|---|---|----------|-----------|-----------|
| sulfur compound biosynthetic process (GO:0044272) | 1/122 | 0.18297 | 1 | 0 | 0 | 4.96771 | 8.4373514 | GSTM1 |
| negative regulation of multicellular organismal process (GO:0051241) | 1/125 | 0.18703 | 1 | 0 | 0 | 4.848485 | 8.1283788 | HPN |
| muscle contraction (GO:0006936) | 1/137 | 0.20309 | 1 | 0 | 0 | 4.4238 | 7.052076 | ACTC1 |
| regulation of signal transduction by p53 class mediator (GO:1901796) | 1/138 | 0.20441 | 1 | 0 | 0 | 4.391744 | 6.972436 | TP63 |
| cellular response to growth factor stimulus (GO:0071363) | 1/139 | 0.20573 | 1 | 0 | 0 | 4.360148 | 6.8941701 | DLX1 |
| inorganic cation transmembrane transport (GO:0098662) | 1/140 | 0.20705 | 1 | 0 | 0 | 4.329004 | 6.8172455 | SLC39A2 |
| positive regulation of cellular process (GO:0048522) | 2/519 | 0.21082 | 1 | 0 | 0 | 2.335494 | 3.6357543 | DLX1;HPN |
| skeletal system development (GO:0001501) | 1/146 | 0.21493 | 1 | 0 | 0 | 4.1511 | 6.3821553 | COMP |
| negative regulation of cell differentiation (GO:0045596) | 1/150 | 0.22013 | 1 | 0 | 0 | 4.040404 | 6.1152452 | HPN |
| negative regulation of transcription from RNA polymerase II promoter (GO:0000122) | 2/565 | 0.23892 | 1 | 0 | 0 | 2.145347 | 3.0713273 | DLX1;TP63 |
| cellular response to lipid (GO:0071396) | 1/178 | 0.25566 | 1 | 0 | 0 | 3.404835 | 4.643936 | OR51E2 |
| organonitrogen compound biosynthetic process (GO:1901566) | 1/181 | 0.25937 | 1 | 0 | 0 | 3.348401 | 4.5187024 | GSTM1 |

| | | | | | | | | |
|---|-------|---------|---|---|---|----------|-----------|-----------|
| protein homooligomerization (GO:0051260) | 1/190 | 0.27039 | 1 | 0 | 0 | 3.189793 | 4.1718434 | TP63 |
| regulation of cell growth (GO:0001558) | 1/201 | 0.28366 | 1 | 0 | 0 | 3.015227 | 3.7991602 | HPN |
| positive regulation of multicellular organismal process (GO:0051240) | 1/202 | 0.28485 | 1 | 0 | 0 | 3.0003 | 3.7677501 | HPN |
| positive regulation of signal transduction (GO:0009967) | 1/206 | 0.28961 | 1 | 0 | 0 | 2.942042 | 3.6458677 | TP63 |
| extracellular matrix organization (GO:0030198) | 1/229 | 0.31637 | 1 | 0 | 0 | 2.646553 | 3.0457851 | COMP |
| apoptotic process (GO:0006915) | 1/231 | 0.31865 | 1 | 0 | 0 | 2.623639 | 3.0005722 | TP63 |
| regulation of programmed cell death (GO:0043067) | 1/268 | 0.35953 | 1 | 0 | 0 | 2.26142 | 2.313359 | TP63 |
| cellular response to oxygen-containing compound (GO:1901701) | 1/274 | 0.36593 | 1 | 0 | 0 | 2.2119 | 2.2236686 | OR51E2 |
| negative regulation of transcription, DNA-templated (GO:0045892) | 2/813 | 0.39035 | 1 | 0 | 0 | 1.490924 | 1.4025394 | DLX1;TP63 |
| positive regulation of apoptotic process (GO:0043065) | 1/307 | 0.40004 | 1 | 0 | 0 | 1.974139 | 1.8086973 | TP63 |
| negative regulation of cell proliferation (GO:0008285) | 1/363 | 0.45389 | 1 | 0 | 0 | 1.669588 | 1.3187992 | HPN |
| transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169) | 1/396 | 0.4834 | 1 | 0 | 0 | 1.530456 | 1.1125026 | HPN |

| | | | | | | | | |
|---|--------|---------|---|---|---|----------|-----------|----------------|
| regulation of transcription, DNA-templated (GO:0006355) | 3/1598 | 0.49746 | 1 | 0 | 0 | 1.137786 | 0.7944509 | SIM2;TP63;HXC6 |
| regulation of intracellular signal transduction (GO:1902531) | 1/422 | 0.50555 | 1 | 0 | 0 | 1.436163 | 0.9796044 | TP63 |
| regulation of gene expression (GO:0010468) | 2/1037 | 0.5162 | 1 | 0 | 0 | 1.168873 | 0.7729199 | ACTC1;HPN |
| negative regulation of nucleic acid-templated transcription (GO:1903507) | 1/444 | 0.52358 | 1 | 0 | 0 | 1.365001 | 0.8832485 | TP63 |
| nervous system development (GO:0007399) | 1/455 | 0.53235 | 1 | 0 | 0 | 1.332001 | 0.8397655 | SIM2 |
| cellular protein metabolic process (GO:0044267) | 1/484 | 0.55473 | 1 | 0 | 0 | 1.252191 | 0.7378823 | SEMG1 |
| positive regulation of nucleic acid-templated transcription (GO:1903508) | 1/502 | 0.5681 | 1 | 0 | 0 | 1.207292 | 0.6826819 | TP63 |
| negative regulation of cellular macromolecule biosynthetic process (GO:2000113) | 1/512 | 0.57535 | 1 | 0 | 0 | 1.183712 | 0.6543248 | TP63 |
| negative regulation of gene expression (GO:0010629) | 1/618 | 0.64535 | 1 | 0 | 0 | 0.980681 | 0.4294996 | TP63 |

| Term | Overlap | P-value | Adjusted P-value | Old P-value | Old Adjusted P- | Odds Ratio | Combined Score | Genes |
|------|---------|---------|------------------|-------------|-----------------|------------|----------------|--|
| | | | | | | | | IGHV5-51;IGHV3-30;IGHV3-21;IGHV3-11;IGHV |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|---|
| <p>t activation, classical pathway (GO:0006958)</p> | 24/123 | 1.99E-48 | 1.01E-44 | 0 | 0 | 125.88513 | 13826.79 | <p>3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4-39;IGHV3-</p> |
| <p>humoral immune response mediated by circulating immunoglobulin (GO:0002455)</p> | 24/125 | 3.05E-48 | 7.78E-45 | 0 | 0 | 123.87097 | 13552.58 | <p>IGHV5-51;IGHV3-30;IGHV3-21;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4-39;IGHV3-</p> |
| <p>regulation of protein activation cascade (GO:2000257)</p> | 18/108 | 6.67E-34 | 1.13E-30 | 0 | 0 | 107.52688 | 8214.042 | <p>IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4-</p> |

| | | | | | | | | |
|---|--------|----------|----------|---|---|-----------|----------|---|
| regulation of acute inflammatory response (GO:0002673) | 18/121 | 6.06E-33 | 4.42E-30 | 0 | 0 | 95.974407 | 7119.651 | 11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| regulation of protein processing (GO:0070613) | 18/128 | 1.79E-32 | 1.14E-29 | 0 | 0 | 90.725806 | 6631.906 | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096) | 18/133 | 3.75E-32 | 2.12E-29 | 0 | 0 | 87.315062 | 6318.314 | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| | | | | | | | | IGHV3-30;IGHV3-11;IGHV3-33;IGHV |

| | | | | | | | | |
|---|--------|----------|----------|---|---|-----------|----------|---|
| -receptor signaling pathway (GO:0038094) | 18/134 | 4.32E-32 | 2.21E-29 | 0 | 0 | 86.663457 | 6258.714 | 1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| Fc receptor mediated stimulatory signaling pathway (GO:0002431) | 18/135 | 4.99E-32 | 2.31E-29 | 0 | 0 | 86.021505 | 6200.096 | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| Fc-epsilon receptor signaling pathway (GO:0038095) | 18/182 | 1.44E-29 | 6.12E-27 | 0 | 0 | 63.807161 | 4237.495 | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| | | | | | | | | IGHV3-30;IGHV3-11;IGHV3-33;IGHV |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|---|
| Fc receptor signaling pathway (GO:0038093) | 18/183 | 1.60E-29 | 6.26E-27 | 0 | 0 | 63.458488 | 4207.808 | 1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| receptor-mediated endocytosis (GO:0006898) | 18/188 | 2.65E-29 | 9.64E-27 | 0 | 0 | 61.770762 | 4064.65 | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| regulation of immune response (GO:0050776) | 18/251 | 5.74E-27 | 1.95E-24 | 0 | 0 | 46.266547 | 2795.553 | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1-2;IGHV4-34;IGHV3-23;IGKV1-5;IGHV4-59;IGLV3-1;IGHV1-46;IGHV4- |
| | | | | | | | | IGHV3-30;IGHV3-11;IGHV3-33;IGHV1- |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|--|
| defense response to bacterium (GO:0042742) | 15/241 | 2.68E-21 | 5.69E-19 | 0 | 0 | 40.155267 | 1902.168 | 3-21;IGHV3-11;IGHV3-33;IGHV1-2;IGHV3-23;IGHV4-59;IGHV |
| antigen receptor-mediated signaling pathway (GO:0050851) | 14/257 | 5.12E-19 | 1.04E-16 | 0 | 0 | 35.144973 | 1480.187 | IGHV5-51;IGHV3-30;IGHV3-21;IGHV3-11;IGHV3-33;IGHV1-2;IGHV3-23;IGHV4- |
| glomerular filtration (GO:000309) | 10-Jan | 0.015396 | 1 | 0 | 0 | 64.516129 | 269.2691 | IGKV3-20 |
| renal filtration | 11-Jan | 0.016923 | 1 | 0 | 0 | 58.651026 | 239.2439 | IGKV3-20 |
| antibacterial humoral response | Jan-35 | 0.052888 | 1 | 0 | 0 | 18.43318 | 54.18574 | IGKV3-20 |
| negative regulation of nucleic acid-templated transcription | 1/444 | 0.501664 | 1 | 0 | 0 | 1.453066 | 1.00236 | ZBED6 |
| negative regulation of cellular macromolecule biosynthetic process | 1/512 | 0.552708 | 1 | 0 | 0 | 1.2600806 | 0.747133 | ZBED6 |
| negative regulation of gene expression | 1/618 | 0.622336 | 1 | 0 | 0 | 1.0439503 | 0.495119 | ZBED6 |
| negative regulation of transcription, DNA- | 1/813 | 0.724029 | 1 | 0 | 0 | 0.7935563 | 0.256258 | ZBED6 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-----------|----------|-------|
| regulation of transcription from RNA polymerase II promoter | 1/1478 | 0.907616 | 1 | 0 | 0 | 0.4365097 | 0.042312 | ZBED6 |
| regulation of transcription, DNA- | 1/1598 | 0.924488 | 1 | 0 | 0 | 0.4037305 | 0.031699 | ZBED6 |

| Term | Overlap | P-value | Adjusted P-value | Old P-value | Old Adjusted P- | Odds Ratio | Combined Score | Genes |
|---|---------|----------|------------------|-------------|-----------------|------------|----------------|---|
| regulation of B cell activation (GO:0050864) | Sep-95 | 7.73E-15 | 3.94E-11 | 0 | 0 | 65.3358 | 2123.018 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| plasma membrane invagination (GO:0099024) | 9/103 | 1.64E-14 | 4.18E-11 | 0 | 0 | 60.2611 | 1912.826 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| positive regulation of lymphocyte activation (GO:0051251) | 9/104 | 1.79E-14 | 3.05E-11 | 0 | 0 | 59.6817 | 1889.085 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| phagocytosis, engulfment (GO:0006911) | 9/104 | 1.79E-14 | 2.29E-11 | 0 | 0 | 59.6817 | 1889.085 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| B cell receptor signaling pathway (GO:0050853) | 9/104 | 1.79E-14 | 1.83E-11 | 0 | 0 | 59.6817 | 1889.085 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |

| | | | | | | | | |
|---|--------|----------|----------|---|---|---------|----------|---|
| positive regulation of B cell activation (GO:0050871) | 9/119 | 6.23E-14 | 5.29E-11 | 0 | 0 | 52.1588 | 1586.024 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| complement activation, classical pathway (GO:0006958) | 9/123 | 8.44E-14 | 6.15E-11 | 0 | 0 | 50.4626 | 1519.092 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| humoral immune response mediated by circulating immunoglobulin (GO:0002455) | 9/125 | 9.79E-14 | 6.24E-11 | 0 | 0 | 49.6552 | 1487.424 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| phagocytosis (GO:0006909) | 9/135 | 1.98E-13 | 1.12E-10 | 0 | 0 | 45.977 | 1344.788 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| defense response to bacterium (GO:0042742) | 10/241 | 8.77E-13 | 4.48E-10 | 0 | 0 | 28.6164 | 794.4509 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2;LTF |
| antigen receptor-mediated signaling pathway (GO:0050851) | 9/257 | 6.64E-11 | 3.08E-08 | 0 | 0 | 24.1513 | 565.9778 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|---------|----------|----------------------------|
| retina homeostasis (GO:0001895) | May-38 | 2.16E-09 | 9.20E-07 | 0 | 0 | 90.7441 | 1810.491 | IGHG3;IGKC;IGHA1;IGHA2;LTF |
| antibacterial humoral response (GO:0019731) | Apr-35 | 1.81E-07 | 7.10E-05 | 0 | 0 | 78.8177 | 1223.681 | IGHM;IGHA1;IGHA2;LTF |
| regulation of protein activation cascade (GO:2000257) | 4/108 | 1.72E-05 | 0.006273 | 0 | 0 | 25.5428 | 280.2054 | IGHG3;IGHG4;IGHG2;IGKC |
| regulation of complement activation (GO:0030449) | 4/109 | 1.78E-05 | 0.006072 | 0 | 0 | 25.3084 | 276.7138 | IGHG3;IGHG4;IGHG2;IGKC |
| regulation of humoral immune response (GO:0002920) | 4/113 | 2.06E-05 | 0.006562 | 0 | 0 | 24.4126 | 263.4484 | IGHG3;IGHG4;IGHG2;IGKC |
| regulation of immune effector process (GO:0002697) | 4/114 | 2.13E-05 | 0.006394 | 0 | 0 | 24.1984 | 260.2973 | IGHG3;IGHG4;IGHG2;IGKC |
| regulation of acute inflammatory response (GO:0002673) | 4/121 | 2.69E-05 | 0.007634 | 0 | 0 | 22.7985 | 239.8931 | IGHG3;IGHG4;IGHG2;IGKC |

| | | | | | | | | |
|---|--------|----------|----------|---|---|---------|----------|------------------------|
| regulation of protein processing (GO:0070613) | 4/128 | 3.36E-05 | 0.009019 | 0 | 0 | 21.5517 | 222.0171 | IGHG3;IGHG4;IGHG2;IGKC |
| Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096) | 4/133 | 3.90E-05 | 0.009955 | 0 | 0 | 20.7415 | 210.5579 | IGHG3;IGHG4;IGHG2;IGKC |
| Fc-gamma receptor signaling pathway (GO:0038094) | 4/134 | 4.02E-05 | 0.009763 | 0 | 0 | 20.5867 | 208.3833 | IGHG3;IGHG4;IGHG2;IGKC |
| Fc receptor mediated stimulatory signaling pathway (GO:0002431) | 4/135 | 4.14E-05 | 0.009594 | 0 | 0 | 20.4342 | 206.2455 | IGHG3;IGHG4;IGHG2;IGKC |
| positive regulation of respiratory burst (GO:0060267) | 08-Feb | 5.65E-05 | 0.012543 | 0 | 0 | 172.414 | 1686.322 | IGHA1;IGHA2 |
| regulation of respiratory burst (GO:0060263) | 10-Feb | 9.07E-05 | 0.019284 | 0 | 0 | 137.931 | 1283.863 | IGHA1;IGHA2 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|---------|----------|-----------------------|
| glomerular filtration (GO:0003094) | 10-Feb | 9.07E-05 | 0.018513 | 0 | 0 | 137.931 | 1283.863 | IGHA1;IGHA2 |
| renal filtration (GO:0097205) | 11-Feb | 1.11E-04 | 0.021737 | 0 | 0 | 125.392 | 1142.098 | IGHA1;IGHA2 |
| receptor-mediated endocytosis (GO:0006898) | 4/188 | 1.49E-04 | 0.02824 | 0 | 0 | 14.6735 | 129.2556 | IGKC;SAA1;IGHA1;IGHA2 |
| positive regulation of metabolic process (GO:0009893) | 18-Feb | 3.06E-04 | 0.055797 | 0 | 0 | 76.6284 | 620.0321 | IGHA1;IGHA2 |
| endocytosis (GO:0006897) | 4/263 | 5.36E-04 | 0.094284 | 0 | 0 | 10.4891 | 79.00078 | IGKC;SAA1;IGHA1;IGHA2 |
| defense response to Gram-negative bacterium (GO:0050829) | Feb-71 | 0.004742 | 0.806543 | 0 | 0 | 19.4269 | 103.9609 | IGHM;LTF |
| epidermis development (GO:0008544) | Feb-81 | 0.006127 | 1 | 0 | 0 | 17.0285 | 86.76096 | KRT17;KRT15 |
| regulation of osteoclast development (GO:2001204) | 06-Jan | 0.00867 | 1 | 0 | 0 | 114.943 | 545.7406 | LTF |

| | | | | | | | | |
|--|--------|----------|---|---|---|---------|----------|----------|
| positive regulation of osteoblast proliferation (GO:0033690) | 06-Jan | 0.00867 | 1 | 0 | 0 | 114.943 | 545.7406 | LTF |
| negative regulation of response to external stimulus (GO:0032102) | 2/107 | 0.010478 | 1 | 0 | 0 | 12.8908 | 58.76237 | SAA1;LTF |
| positive regulation of toll-like receptor 4 signaling pathway (GO:0034145) | 08-Jan | 0.011543 | 1 | 0 | 0 | 86.2069 | 384.6258 | LTF |
| regulation of interleukin-1 secretion (GO:0050704) | 09-Jan | 0.012977 | 1 | 0 | 0 | 76.6284 | 332.9176 | SAA1 |
| membrane disruption in other organism (GO:0051673) | 09-Jan | 0.012977 | 1 | 0 | 0 | 76.6284 | 332.9176 | LTF |
| macrophage migration (GO:1905517) | 10-Jan | 0.014409 | 1 | 0 | 0 | 68.9655 | 292.4078 | SAA1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|---------|----------|------|
| macrophage chemotaxis (GO:0048246) | 10-Jan | 0.014409 | 1 | 0 | 0 | 68.9655 | 292.4078 | SAA1 |
| negative regulation of lipopolysaccharide-mediated signaling pathway (GO:0031665) | 10-Jan | 0.014409 | 1 | 0 | 0 | 68.9655 | 292.4078 | LTF |
| negative regulation by host of viral process (GO:0044793) | 10-Jan | 0.014409 | 1 | 0 | 0 | 68.9655 | 292.4078 | LTF |
| modulation by host of viral process (GO:0044788) | 11-Jan | 0.015839 | 1 | 0 | 0 | 62.6959 | 259.8935 | LTF |
| positive regulation of interleukin-1 production (GO:0032732) | 12-Jan | 0.017266 | 1 | 0 | 0 | 57.4713 | 233.2752 | SAA1 |
| negative regulation of ATPase activity (GO:0032780) | 12-Jan | 0.017266 | 1 | 0 | 0 | 57.4713 | 233.2752 | LTF |

| | | | | | | | | |
|---|--------|----------|---|---|---|---------|----------|------|
| regulation of peptide secretion (GO:0002791) | 15-Jan | 0.021538 | 1 | 0 | 0 | 45.977 | 176.457 | SAA1 |
| regulation of toll-like receptor 4 signaling pathway (GO:0034143) | 16-Jan | 0.022958 | 1 | 0 | 0 | 43.1034 | 162.6767 | LTF |
| regulation of osteoblast proliferation (GO:0033688) | 16-Jan | 0.022958 | 1 | 0 | 0 | 43.1034 | 162.6767 | LTF |
| bone morphogenesis (GO:0060349) | 16-Jan | 0.022958 | 1 | 0 | 0 | 43.1034 | 162.6767 | LTF |
| negative regulation of cell development (GO:0010721) | 17-Jan | 0.024376 | 1 | 0 | 0 | 40.568 | 150.6764 | LTF |
| defense response to fungus (GO:0050832) | 17-Jan | 0.024376 | 1 | 0 | 0 | 40.568 | 150.6764 | LTF |
| negative regulation of osteoclast differentiation (GO:0045671) | 18-Jan | 0.025791 | 1 | 0 | 0 | 38.3142 | 140.1422 | LTF |

| | | | | | | | | |
|--|--------|----------|---|---|---|---------|----------|------|
| regulation of lipopolysaccharide-mediated signaling pathway (GO:0031664) | 18-Jan | 0.025791 | 1 | 0 | 0 | 38.3142 | 140.1422 | LTF |
| regulation of viral process (GO:0050792) | 18-Jan | 0.025791 | 1 | 0 | 0 | 38.3142 | 140.1422 | LTF |
| acute-phase response (GO:0006953) | 18-Jan | 0.025791 | 1 | 0 | 0 | 38.3142 | 140.1422 | SAA1 |
| positive regulation of toll-like receptor signaling pathway (GO:0034123) | 19-Jan | 0.027205 | 1 | 0 | 0 | 36.2976 | 130.8291 | LTF |
| innate immune response in mucosa (GO:0002227) | 19-Jan | 0.027205 | 1 | 0 | 0 | 36.2976 | 130.8291 | LTF |
| negative regulation of response to biotic stimulus (GO:0002832) | 19-Jan | 0.027205 | 1 | 0 | 0 | 36.2976 | 130.8291 | LTF |

| | | | | | | | | |
|---|--------|----------|---|---|---|---------|----------|------|
| negative regulation of viral process (GO:0048525) | 21-Jan | 0.030027 | 1 | 0 | 0 | 32.8407 | 115.1282 | LTF |
| mucosal immune response (GO:0002385) | 24-Jan | 0.034245 | 1 | 0 | 0 | 28.7356 | 96.96019 | LTF |
| regulation of protein transport (GO:0051223) | 27-Jan | 0.038445 | 1 | 0 | 0 | 25.5428 | 83.23172 | SAA1 |
| acute inflammatory response (GO:0002526) | 28-Jan | 0.039841 | 1 | 0 | 0 | 24.6305 | 79.38056 | SAA1 |
| positive regulation of interleukin-1 secretion (GO:0050716) | 29-Jan | 0.041235 | 1 | 0 | 0 | 23.7812 | 75.82535 | SAA1 |
| negative regulation of tumor necrosis factor superfamily cytokine production (GO:1903556) | 31-Jan | 0.044018 | 1 | 0 | 0 | 22.2469 | 69.48069 | LTF |

| | | | | | | | | |
|--|--------|----------|---|---|---|---------|----------|--------|
| regulation of cytokine secretion (GO:0050707) | 31-Jan | 0.044018 | 1 | 0 | 0 | 22.2469 | 69.48069 | SAA1 |
| positive regulation of bone mineralization (GO:0030501) | 31-Jan | 0.044018 | 1 | 0 | 0 | 22.2469 | 69.48069 | LTF |
| skeletal system morphogenesis (GO:0048705) | 31-Jan | 0.044018 | 1 | 0 | 0 | 22.2469 | 69.48069 | LTF |
| negative regulation of multi-organism process (GO:0043901) | Jan-33 | 0.046793 | 1 | 0 | 0 | 20.8986 | 63.99223 | LTF |
| bone development (GO:0060348) | Jan-34 | 0.048177 | 1 | 0 | 0 | 20.284 | 61.51868 | LTF |
| positive regulation of osteoblast differentiation (GO:0045669) | Jan-35 | 0.04956 | 1 | 0 | 0 | 19.7044 | 59.20353 | LTF |
| endothelial cell migration (GO:0043542) | Jan-35 | 0.04956 | 1 | 0 | 0 | 19.7044 | 59.20353 | S100A2 |

| | | | | | | | | |
|--|--------|----------|---|---|---|---------|----------|--------|
| regulation of cysteine-type endopeptidase activity (GO:2000116) | Jan-36 | 0.05094 | 1 | 0 | 0 | 19.1571 | 57.03264 | LTF |
| epithelial cell migration (GO:0010631) | Jan-36 | 0.05094 | 1 | 0 | 0 | 19.1571 | 57.03264 | S100A2 |
| regulation of ATPase activity (GO:0043462) | Jan-40 | 0.056443 | 1 | 0 | 0 | 17.2414 | 49.56075 | LTF |
| lymphocyte chemotaxis (GO:0048247) | Jan-44 | 0.061915 | 1 | 0 | 0 | 15.674 | 43.60488 | SAA1 |
| antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844) | Jan-49 | 0.068712 | 1 | 0 | 0 | 14.0746 | 37.68938 | LTF |
| negative regulation of viral genome replication (GO:0045071) | Jan-50 | 0.070066 | 1 | 0 | 0 | 13.7931 | 36.6665 | LTF |

| | | | | | | | | |
|---|--------|----------|---|---|---|---------|----------|------|
| positive regulation of ossification (GO:0045778) | Jan-52 | 0.072767 | 1 | 0 | 0 | 13.2626 | 34.75447 | LTF |
| neutrophil chemotaxis (GO:0030593) | Jan-53 | 0.074115 | 1 | 0 | 0 | 13.0124 | 33.85988 | SAA1 |
| granulocyte chemotaxis (GO:0071621) | Jan-56 | 0.078148 | 1 | 0 | 0 | 12.3153 | 31.39348 | SAA1 |
| regulation of secretion by cell (GO:1903530) | Jan-56 | 0.078148 | 1 | 0 | 0 | 12.3153 | 31.39348 | SAA1 |
| neutrophil migration (GO:1990266) | Jan-58 | 0.080827 | 1 | 0 | 0 | 11.8906 | 29.91015 | SAA1 |
| cell chemotaxis (GO:0060326) | Jan-60 | 0.083499 | 1 | 0 | 0 | 11.4943 | 28.53939 | SAA1 |
| negative regulation of viral life cycle (GO:1903901) | Jan-61 | 0.084831 | 1 | 0 | 0 | 11.3058 | 27.89247 | LTF |
| regulation of tumor necrosis factor production (GO:0032680) | Jan-61 | 0.084831 | 1 | 0 | 0 | 11.3058 | 27.89247 | LTF |

| | | | | | | | | |
|--|--------|----------|---|---|---|---------|----------|------|
| regulation of viral genome replication (GO:0045069) | Jan-63 | 0.087492 | 1 | 0 | 0 | 10.9469 | 26.66899 | LTF |
| positive regulation of cell adhesion (GO:0045785) | Jan-64 | 0.088819 | 1 | 0 | 0 | 10.7759 | 26.09003 | SAA1 |
| regulation of osteoblast differentiation (GO:0045667) | Jan-69 | 0.095428 | 1 | 0 | 0 | 9.995 | 23.48213 | LTF |
| negative regulation of cysteine-type endopeptidase activity (GO:2000117) | Jan-72 | 0.099371 | 1 | 0 | 0 | 9.57854 | 22.11589 | LTF |
| positive regulation of cytokine secretion (GO:0050715) | Jan-73 | 0.100681 | 1 | 0 | 0 | 9.44733 | 21.68914 | SAA1 |
| negative regulation of inflammatory response (GO:0050728) | Jan-78 | 0.107207 | 1 | 0 | 0 | 8.84173 | 19.74355 | SAA1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|---------|----------|------------|
| regulation of protein serine/threonine kinase activity (GO:0071900) | Jan-80 | 0.109804 | 1 | 0 | 0 | 8.62069 | 19.04359 | LTF |
| negative regulation of defense response (GO:0031348) | Jan-80 | 0.109804 | 1 | 0 | 0 | 8.62069 | 19.04359 | SAA1 |
| positive regulation of protein secretion (GO:0050714) | Jan-82 | 0.112394 | 1 | 0 | 0 | 8.41043 | 18.38303 | SAA1 |
| negative regulation of endopeptidase activity (GO:0010951) | Jan-83 | 0.113687 | 1 | 0 | 0 | 8.3091 | 18.06655 | LTF |
| cellular response to cytokine stimulus (GO:0071345) | 2/456 | 0.140982 | 1 | 0 | 0 | 3.0248 | 5.925972 | IGHG4;SAA1 |
| regulation of protein secretion (GO:0050708) | 1/107 | 0.144163 | 1 | 0 | 0 | 6.44538 | 12.48347 | SAA1 |

| | | | | | | | | |
|--|-------|----------|---|---|---|---------|----------|----------|
| negative regulation of hydrolase activity (GO:0051346) | 1/108 | 0.145411 | 1 | 0 | 0 | 6.3857 | 12.31286 | LTF |
| regulation of cytokine production (GO:0001817) | 1/108 | 0.145411 | 1 | 0 | 0 | 6.3857 | 12.31286 | LTF |
| negative regulation of cell growth (GO:0030308) | 1/115 | 0.154095 | 1 | 0 | 0 | 5.997 | 11.21551 | SCGB3A1 |
| cellular protein metabolic process (GO:0044267) | 2/484 | 0.155045 | 1 | 0 | 0 | 2.84981 | 5.312168 | SAA1;LTF |
| activation of MAPK activity (GO:0000187) | 1/117 | 0.156561 | 1 | 0 | 0 | 5.89449 | 10.93022 | SAA1 |
| positive regulation of protein serine/threonine kinase activity (GO:0071902) | 1/118 | 0.157791 | 1 | 0 | 0 | 5.84454 | 10.79185 | LTF |
| negative regulation of growth (GO:0045926) | 1/120 | 0.160246 | 1 | 0 | 0 | 5.74713 | 10.52325 | SCGB3A1 |

| | | | | | | | | |
|---|-------|----------|---|---|---|---------|----------|------|
| positive regulation of NF-kappaB transcription factor activity (GO:0051092) | 1/128 | 0.169998 | 1 | 0 | 0 | 5.38793 | 9.547253 | LTF |
| positive regulation of cytosolic calcium ion concentration (GO:0007204) | 1/133 | 0.176037 | 1 | 0 | 0 | 5.18538 | 9.007318 | SAA1 |
| regulation of cytosolic calcium ion concentration (GO:0051480) | 1/137 | 0.180838 | 1 | 0 | 0 | 5.03398 | 8.608884 | SAA1 |
| positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123) | 1/163 | 0.211391 | 1 | 0 | 0 | 4.23101 | 6.575186 | LTF |
| regulation of inflammatory response (GO:0050727) | 1/166 | 0.214845 | 1 | 0 | 0 | 4.15455 | 6.389028 | SAA1 |

| | | | | | | | | |
|---|-------|----------|---|---|---|---------|----------|------------|
| positive regulation of protein kinase activity (GO:0045860) | 1/172 | 0.221709 | 1 | 0 | 0 | 4.00962 | 6.040061 | LTF |
| positive regulation of MAP kinase activity (GO:0043406) | 1/177 | 0.227384 | 1 | 0 | 0 | 3.89636 | 5.770951 | SAA1 |
| Fc-epsilon receptor signaling pathway (GO:0038095) | 1/182 | 0.23302 | 1 | 0 | 0 | 3.78931 | 5.519638 | IGKC |
| cytokine-mediated signaling pathway (GO:0019221) | 2/633 | 0.233501 | 1 | 0 | 0 | 2.17901 | 3.169512 | IGHG4;SAA1 |
| Fc receptor signaling pathway (GO:0038093) | 1/183 | 0.234142 | 1 | 0 | 0 | 3.76861 | 5.471368 | IGKC |
| positive regulation of cell differentiation (GO:0045597) | 1/194 | 0.246383 | 1 | 0 | 0 | 3.55492 | 4.979972 | LTF |
| regulation of cell growth (GO:0001558) | 1/201 | 0.254075 | 1 | 0 | 0 | 3.43112 | 4.701068 | SCGB3A1 |

| | | | | | | | | |
|---|-------|----------|---|---|---|---------|----------|------|
| regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122) | 1/204 | 0.257348 | 1 | 0 | 0 | 3.38066 | 4.588662 | LTF |
| positive regulation of sequence-specific DNA binding transcription factor activity (GO:0051091) | 1/215 | 0.269231 | 1 | 0 | 0 | 3.2077 | 4.209095 | LTF |
| positive regulation of cytokine production (GO:0001819) | 1/220 | 0.274572 | 1 | 0 | 0 | 3.1348 | 4.05186 | SAA1 |
| activation of protein kinase activity (GO:0032147) | 1/233 | 0.288281 | 1 | 0 | 0 | 2.95989 | 3.681573 | SAA1 |
| regulation of immune response (GO:0050776) | 1/251 | 0.306851 | 1 | 0 | 0 | 2.74763 | 3.246029 | IGKC |
| negative regulation of signal transduction (GO:0009968) | 1/283 | 0.338716 | 1 | 0 | 0 | 2.43694 | 2.63822 | LTF |

| | | | | | | | | |
|---|-------|----------|---|---|---|---------|----------|-----|
| negative regulation of programmed cell death (GO:0043069) | 1/408 | 0.450166 | 1 | 0 | 0 | 1.69033 | 1.349117 | LTF |
| positive regulation of cell proliferation (GO:0008284) | 1/424 | 0.46305 | 1 | 0 | 0 | 1.62655 | 1.252312 | LTF |
| neutrophil degranulation (GO:0043312) | 1/479 | 0.50515 | 1 | 0 | 0 | 1.43978 | 0.983228 | LTF |
| positive regulation of intracellular signal transduction (GO:1902533) | 1/479 | 0.50515 | 1 | 0 | 0 | 1.43978 | 0.983228 | LTF |
| neutrophil activation involved in immune response (GO:0002283) | 1/483 | 0.508084 | 1 | 0 | 0 | 1.42786 | 0.966815 | LTF |
| negative regulation of apoptotic process (GO:0043066) | 1/485 | 0.509545 | 1 | 0 | 0 | 1.42197 | 0.958746 | LTF |

| | | | | | | | | |
|---|-------|----------|---|---|---|---------|----------|-----|
| neutrophil mediated immunity (GO:0002446) | 1/487 | 0.511001 | 1 | 0 | 0 | 1.41613 | 0.950766 | LTF |
|---|-------|----------|---|---|---|---------|----------|-----|

| | | | | | | | | |
|--|-------|----------|---|---|---|---------|----------|---------|
| negative regulation of cellular process (GO:0048523) | 1/534 | 0.544054 | 1 | 0 | 0 | 1.29149 | 0.786139 | SCGB3A1 |
| regulation of cell proliferation (GO:0042127) | 1/740 | 0.66517 | 1 | 0 | 0 | 0.93197 | 0.379975 | SCGB3A1 |
| regulation of apoptotic process (GO:0042981) | 1/815 | 0.701015 | 1 | 0 | 0 | 0.8462 | 0.300593 | LTF |

Data S1: Enrichment analysis for Biological Process using the tool Enrich.

Data S2

| | |
|---------------------|---|
| Data S2 | Enrichment analysis for Biological Pathways using the tool Enrich |
| Reactome_2016 | |
| Tab Content: | |
| Tab 1 | PC1 |
| Tab 2 | PC2 |
| Tab 3 | PC3 |

| Term | Overlap | P-value | Adjusted P-value | Old P-value | Old Adjusted P-value | Odds Ratio | Combined Score | Genes |
|--|---------|----------|------------------|-------------|----------------------|------------|----------------|-------|
| Signaling by MST1 Homo sapiens R-HSA-8852405 | 05-Jan | 0.008224 | 1 | 0 | 0 | 121.21212 | 581.9095 | HPN |

| | | | | | | | | |
|--|--------|----------|---|---|---|-----------|----------|---------------|
| TP53 Regulates Metabolic Genes Homo sapiens R-HSA- 5628897 | Feb-84 | 0.008458 | 1 | 0 | 0 | 14.430014 | 68.8694 | GPX2;T P63 |
| Synthesis of 5- eicosatetraen oic acids Homo sapiens R-HSA- 2142688 | 06-Jan | 0.00986 | 1 | 0 | 0 | 101.0101 | 466.589 | GPX2 |
| Synthesis of 15- eicosatetraen oic acid derivatives Homo sapiens R-HSA- 2142770 | 06-Jan | 0.00986 | 1 | 0 | 0 | 101.0101 | 466.589 | GPX2 |
| Synthesis of 12- eicosatetraen oic acid derivatives Homo sapiens R-HSA- 2142712 | 06-Jan | 0.00986 | 1 | 0 | 0 | 101.0101 | 466.589 | GPX2 |
| Activation of PUMA and translocation to mitochondria Homo sapiens R-HSA-139915 | 08-Jan | 0.013126 | 1 | 0 | 0 | 75.757576 | 328.2687 | TP63 |
| Zinc influx into cells by the SLC39 gene family Homo sapiens R-HSA-442380 | 10-Jan | 0.016382 | 1 | 0 | 0 | 60.606061 | 249.1879 | SLC39A 2 |

| | | | | | | | | |
|--|--------|----------|---|---|---|-----------|----------|-------------|
| TP53 Regulates Transcription of Caspase Activators and Caspases Homo sapiens R-HSA- 6803207 | 12-Jan | 0.019626 | 1 | 0 | 0 | 50.505051 | 198.529 | TP63 |
| TP53 Regulates Transcription of Death Receptors and Ligands Homo sapiens R-HSA- 6803211 | 12-Jan | 0.019626 | 1 | 0 | 0 | 50.505051 | 198.529 | TP63 |
| Regulation of TP53 Activity through Association with Co- factors Homo sapiens R-HSA- 6804759 | 14-Jan | 0.022861 | 1 | 0 | 0 | 43.290043 | 163.5636 | TP63 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53- dependent apoptosis remain uncertain Homo sapiens R-HSA- 6803205 | 14-Jan | 0.022861 | 1 | 0 | 0 | 43.290043 | 163.5636 | TP63 |
| Zinc transporters Homo sapiens R-HSA-435354 | 17-Jan | 0.027694 | 1 | 0 | 0 | 35.650624 | 127.863 | SLC39A 2 |

| | | | | | | | | |
|--|--------|----------|---|---|---|-----------|----------|--------------|
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release Homo sapiens R-HSA- 6803204 | 19-Jan | 0.030902 | 1 | 0 | 0 | 31.897927 | 110.9067 | TP63 |
| Common Pathway of Fibrin Clot Formation Homo sapiens R-HSA-140875 | 22-Jan | 0.035696 | 1 | 0 | 0 | 27.548209 | 91.81023 | SERPIN A5 |
| Intrinsic Pathway of Fibrin Clot Formation Homo sapiens R-HSA-140837 | 22-Jan | 0.035696 | 1 | 0 | 0 | 27.548209 | 91.81023 | SERPIN A5 |
| Metal ion SLC transporters Homo sapiens R-HSA-425410 | 25-Jan | 0.040467 | 1 | 0 | 0 | 24.242424 | 77.75191 | SLC39A 2 |
| Activation of BH3-only proteins Homo sapiens R-HSA-114452 | 29-Jan | 0.046793 | 1 | 0 | 0 | 20.898642 | 63.99223 | TP63 |
| PIWI- interacting RNA (piRNA) biogenesis Homo sapiens R-HSA- 5601884 | 29-Jan | 0.046793 | 1 | 0 | 0 | 20.898642 | 63.99223 | TDRD1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-----------|----------|----------|
| Detoxification of Reactive Oxygen Species Homo sapiens R-HSA-3299685 | Jan-33 | 0.053078 | 1 | 0 | 0 | 18.365473 | 53.92095 | GPX2 |
| Glutathione conjugation Homo sapiens R-HSA-156590 | Jan-38 | 0.060878 | 1 | 0 | 0 | 15.948963 | 44.63934 | GSTM1 |
| Formation of Fibrin Clot (Clotting Cascade) Homo sapiens R-HSA-140877 | Jan-39 | 0.06243 | 1 | 0 | 0 | 15.540016 | 43.10341 | SERPINA5 |
| Intrinsic Pathway for Apoptosis Homo sapiens R-HSA-109606 | Jan-42 | 0.067073 | 1 | 0 | 0 | 14.430014 | 38.98955 | TP63 |
| TP53 Regulates Transcription of Cell Death Genes Homo sapiens R-HSA-5633008 | Jan-43 | 0.068615 | 1 | 0 | 0 | 14.094433 | 37.76233 | TP63 |
| Arachidonic acid metabolism Homo sapiens R-HSA-2142753 | Jan-53 | 0.083906 | 1 | 0 | 0 | 11.435106 | 28.3369 | GPX2 |
| ECM proteoglycans Homo sapiens R-HSA-3000178 | Jan-55 | 0.086934 | 1 | 0 | 0 | 11.019284 | 26.91572 | COMP |

| | | | | | | | | |
|---|--------|----------|---|---|---|-----------|----------|-----------|
| Integrin cell surface interactions Homo sapiens R-HSA-216083 | Jan-67 | 0.104904 | 1 | 0 | 0 | 9.0456807 | 20.3954 | COMP |
| Amyloid fiber formation Homo sapiens R-HSA-977225 | Jan-68 | 0.106386 | 1 | 0 | 0 | 8.912656 | 19.97045 | SEMG1 |
| Transcriptional Regulation by TP53 Homo sapiens R-HSA-3700989 | 2/348 | 0.112134 | 1 | 0 | 0 | 3.4831069 | 7.62124 | GPX2;TP63 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis Homo sapiens R-HSA-5617472 | Jan-89 | 0.136961 | 1 | 0 | 0 | 6.8096697 | 13.53802 | HOXC4 |
| Activation of HOX genes during differentiation Homo sapiens R-HSA-5619507 | Jan-89 | 0.136961 | 1 | 0 | 0 | 6.8096697 | 13.53802 | HOXC4 |
| Phase II conjugation Homo sapiens R-HSA-156580 | 1/100 | 0.152569 | 1 | 0 | 0 | 6.0606061 | 11.39477 | GSTM1 |

| | | | | | | | | |
|---|-------|----------|---|---|---|-----------|----------|---------|
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds Homo sapiens R-HSA-425366 | 1/101 | 0.153975 | 1 | 0 | 0 | 6.0006001 | 11.22693 | SLC39A2 |
| Gene Silencing by RNA Homo sapiens R-HSA-211000 | 1/101 | 0.153975 | 1 | 0 | 0 | 6.0006001 | 11.22693 | TDRD1 |
| Regulation of TP53 Activity Homo sapiens R-HSA-5633007 | 1/151 | 0.22143 | 1 | 0 | 0 | 4.0136464 | 6.051177 | TP63 |
| Apoptosis Homo sapiens R-HSA-109581 | 1/163 | 0.236825 | 1 | 0 | 0 | 3.7181632 | 5.355761 | TP63 |
| Programmed Cell Death Homo sapiens R-HSA-5357801 | 1/166 | 0.240628 | 1 | 0 | 0 | 3.6509675 | 5.200813 | TP63 |
| Biological oxidations Homo sapiens R-HSA-211859 | 1/199 | 0.281263 | 1 | 0 | 0 | 3.0455307 | 3.863152 | GSTM1 |
| SLC-mediated transmembrane transport Homo sapiens R-HSA-425407 | 1/268 | 0.359527 | 1 | 0 | 0 | 2.2614202 | 2.313359 | SLC39A2 |

| | | | | | | | | |
|--|--------|----------|---|---|---|-----------|----------|-----------------|
| Extracellular matrix organization Homo sapiens R-HSA-1474244 | 1/283 | 0.375412 | 1 | 0 | 0 | 2.1415569 | 2.098148 | COMP |
| Generic Transcription Pathway Homo sapiens R-HSA-212436 | 2/812 | 0.389754 | 1 | 0 | 0 | 1.4927601 | 1.406538 | GPX2;TP63 |
| Cellular responses to stress Homo sapiens R-HSA-2262752 | 1/367 | 0.457555 | 1 | 0 | 0 | 1.6513913 | 1.291156 | GPX2 |
| Olfactory Signaling Pathway Homo sapiens R-HSA-381753 | 1/418 | 0.502208 | 1 | 0 | 0 | 1.4499058 | 0.998611 | OR51E2 |
| Gene Expression Homo sapiens R-HSA-74160 | 3/1631 | 0.511556 | 1 | 0 | 0 | 1.1147651 | 0.747225 | TDRD1;GPX2;TP63 |
| Hemostasis Homo sapiens R-HSA-109582 | 1/552 | 0.603212 | 1 | 0 | 0 | 1.0979359 | 0.554992 | SERPINA5 |
| Transmembrane transport of small molecules Homo sapiens R-HSA-382551 | 1/594 | 0.630556 | 1 | 0 | 0 | 1.0203041 | 0.470517 | SLC39A2 |
| Metabolism of lipids and lipoproteins Homo sapiens R-HSA-556833 | 1/659 | 0.669307 | 1 | 0 | 0 | 0.9196671 | 0.369257 | GPX2 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-----------|----------|----------------|
| Developmental Biology Homo sapiens R-HSA-1266738 | 1/786 | 0.733971 | 1 | 0 | 0 | 0.7710695 | 0.238481 | HOXC4 |
| GPCR downstream signaling Homo sapiens R-HSA-388396 | 1/983 | 0.81072 | 1 | 0 | 0 | 0.6165418 | 0.129371 | OR51E2 |
| Metabolism Homo sapiens R-HSA-1430728 | Feb-08 | 0.83641 | 1 | 0 | 0 | 0.6352837 | 0.113485 | GPX2; GSTM1 |
| Metabolism of proteins Homo sapiens R-HSA-392499 | 1/1074 | 0.838451 | 1 | 0 | 0 | 0.5643022 | 0.099429 | SEMG1 |
| Signaling by GPCR Homo sapiens R-HSA-372790 | 1/1293 | 0.890009 | 1 | 0 | 0 | 0.4687244 | 0.054618 | OR51E2 |
| Signal Transduction Homo sapiens R-HSA-162582 | Feb-65 | 0.926692 | 1 | 0 | 0 | 0.4917327 | 0.037438 | HPN; OR51E2 |

| Term | Overlap | P-value | Adjusted P-value | Old P-value | Old Adjusted P-value | Odds Ratio | Combined Score | Genes |
|---|---------|----------|------------------|-------------|----------------------|------------|----------------|--|
| Classical antibody-mediated complement activation Homo sapiens R-HSA-173623 | Jul-43 | 3.21E-13 | 4.92E-10 | 0 | 0 | 105.02626 | 3021.174 | IGLV2-11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|--|
| Scavenging of heme from plasma Homo sapiens R-HSA-2168880 | Jul-46 | 5.32E-13 | 4.07E-10 | 0 | 0 | 98.176718 | 2774.632 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |
| FCGR activation Homo sapiens R-HSA-2029481 | Jul-49 | 8.52E-13 | 4.34E-10 | 0 | 0 | 92.165899 | 2561.447 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |
| Creation of C4 and C2 activators Homo sapiens R-HSA-166786 | Jul-49 | 8.52E-13 | 3.26E-10 | 0 | 0 | 92.165899 | 2561.447 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |
| Initial triggering of complement Homo sapiens R-HSA-166663 | Jul-58 | 2.95E-12 | 9.04E-10 | 0 | 0 | 77.864294 | 2067.165 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |

| | | | | | | | | |
|---|--------|----------|----------|---|---|-----------|----------|---|
| Role of phospholipids in phagocytosis Homo sapiens R-HSA-2029485 | Jul-60 | 3.78E-12 | 9.65E-10 | 0 | 0 | 75.268817 | 1979.574 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| FCERI mediated Ca+2 mobilization Homo sapiens R-HSA-2871809 | Jul-62 | 4.81E-12 | 1.05E-09 | 0 | 0 | 72.840791 | 1898.265 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| Binding and Uptake of Ligands by Scavenger Receptors Homo sapiens R-HSA-2173782 | Jul-74 | 1.74E-11 | 3.32E-09 | 0 | 0 | 61.028771 | 1512.038 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| Complement cascade Homo sapiens R-HSA-166658 | Jul-80 | 3.05E-11 | 5.18E-09 | 0 | 0 | 56.451613 | 1366.91 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|--|
| Regulation of actin dynamics for phagocytic cup formation Homo sapiens R-HSA-2029482 | Jul-97 | 1.21E-10 | 1.85E-08 | 0 | 0 | 46.558031 | 1063.129 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |
| FCERI mediated NF-kB activation Homo sapiens R-HSA-2871837 | 7/111 | 3.15E-10 | 4.39E-08 | 0 | 0 | 40.685847 | 890.084 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |
| Fcgamma receptor (FCGR) dependent phagocytosis Homo sapiens R-HSA-2029480 | 7/120 | 5.47E-10 | 6.98E-08 | 0 | 0 | 37.634409 | 802.5911 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Homo sapiens R-HSA-198933 | 7/157 | 3.60E-09 | 4.24E-07 | 0 | 0 | 28.765153 | 559.2261 | IGLV2- 11;IGLV 3-25;IGLV 1-40;IGHV 3-23;IGKV 1-5;IGLV2-23;IGKV 4-1 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|---|
| Role of LAT2/NTAL/LAB on calcium mobilization Homo sapiens R-HSA-2730905 | 7/162 | 4.48E-09 | 4.90E-07 | 0 | 0 | 27.87734 | 535.877 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| FCERI mediated MAPK activation Homo sapiens R-HSA-2871796 | 7/289 | 2.39E-07 | 2.44E-05 | 0 | 0 | 15.626744 | 238.259 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| Fc epsilon receptor (FCERI) signaling Homo sapiens R-HSA-2454202 | 7/395 | 1.94E-06 | 1.86E-04 | 0 | 0 | 11.433238 | 150.3733 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| CD22 mediated BCR regulation Homo sapiens R-HSA-5690714 | 18-Mar | 2.71E-06 | 2.44E-04 | 0 | 0 | 107.52688 | 1378.414 | IGHV3- 23;IGKV1-5;IGKV4-1 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|---|
| Vesicle-mediated transport Homo sapiens R-HSA-5653656 | 7/492 | 8.23E-06 | 7.00E-04 | 0 | 0 | 9.179124 | 107.4662 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Homo sapiens R-HSA-983695 | Mar-47 | 5.22E-05 | 0.004204 | 0 | 0 | 41.180508 | 406.0558 | IGHV3- 23;IGKV1-5;IGKV4-1 |
| Adaptive Immune System Homo sapiens R-HSA-1280218 | 7/762 | 1.34E-04 | 0.010242 | 0 | 0 | 5.9266785 | 52.85753 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |
| Innate Immune System Homo sapiens R-HSA-168249 | 7/807 | 1.91E-04 | 0.01391 | 0 | 0 | 5.5961946 | 47.92384 | IGLV2- 11;IGLV3-25;IGLV1-40;IGHV3-23;IGKV1-5;IGLV2-23;IGKV4-1 |

| | | | | | | | | |
|--|--------|----------|----------|---|---|-----------|----------|---|
| Signaling by the B Cell Receptor (BCR) Homo sapiens R-HSA-983705 | 3/233 | 0.005516 | 0.383581 | 0 | 0 | 8.3067977 | 43.19689 | IGHV3- 23;IGKV 1- 5;IGKV4- 1 |
| Immune System Homo sapiens R-HSA-168256 | 7/1547 | 0.008258 | 0.549342 | 0 | 0 | 2.9192819 | 14.00252 | IGLV2- 11;IGLV 3- 25;IGLV 1- 40;IGHV 3- 23;IGKV 1- 5;IGLV2- 23;IGKV 4-1 |

| Term | Overlap | P-value | Adjusted P-value | Old P-value | Old Adjusted P-value | Odds Ratio | Combined Score | Genes |
|---|---------|----------|------------------|-------------|----------------------|-------------|----------------|------------------------------------|
| Classical antibody-mediated complement activation Homo sapiens R-HSA-173623 | Jun-43 | 3.14E-11 | 4.81E-08 | 0 | 0 | 96.23095429 | 2327.190639 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |
| FCGR activation Homo sapiens R-HSA-2029481 | Jun-49 | 7.17E-11 | 5.48E-08 | 0 | 0 | 84.44757213 | 1972.619435 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |
| Creation of C4 and C2 activators Homo sapiens R-HSA-166786 | Jun-49 | 7.17E-11 | 3.65E-08 | 0 | 0 | 84.44757213 | 1972.619435 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |

| | | | | | | | | |
|---|--------|----------|----------|---|---|-------------|-------------|------------------------------------|
| Initial triggering of complement Homosapiens R-HSA-166663 | Jun-58 | 2.06E-10 | 7.86E-08 | 0 | 0 | 71.34363853 | 1591.3323 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |
| Role of phospholipids in phagocytosis Homosapiens R-HSA-2029485 | Jun-60 | 2.54E-10 | 7.77E-08 | 0 | 0 | 68.96551724 | 1523.761332 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |
| Binding and Uptake of Ligands by Scavenger Receptors Homosapiens R-HSA-2173782 | Jun-74 | 9.26E-10 | 2.36E-07 | 0 | 0 | 55.91798695 | 1163.090332 | IGKC;IGLC3;SAA1;IGLC2;IGHA1;IGHA2 |
| Complement cascade Homosapiens R-HSA-166658 | Jun-80 | 1.49E-09 | 3.26E-07 | 0 | 0 | 51.72413793 | 1051.143801 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |
| Regulation of actin dynamics for phagocytic cup formation Homosapiens R-HSA-2029482 | Jun-97 | 4.83E-09 | 9.24E-07 | 0 | 0 | 42.65908283 | 816.8568044 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |

| | | | | | | | | |
|---|--------|----------|----------|---|---|-------------|-------------|------------------------------------|
| Scavenging of heme from plasma Homo sapiens R-HSA-2168880 | May-46 | 5.86E-09 | 9.96E-07 | 0 | 0 | 74.96251874 | 1420.912392 | IGKC;IGLC3;IGLC2;IGHA1;IGHA2 |
| CD22 mediated BCR regulation Homo sapiens R-HSA-5690714 | 18-Apr | 1.08E-08 | 1.64E-06 | 0 | 0 | 153.256705 | 2811.987286 | IGHM;IGKC;IGLC3;IGLC2 |
| Fc gamma receptor (FCGR) dependent phagocytosis Homo sapiens R-HSA-2029480 | 6/120 | 1.75E-08 | 2.43E-06 | 0 | 0 | 34.48275862 | 615.9940625 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;IGLC2 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Homo sapiens R-HSA-983695 | Apr-47 | 6.09E-07 | 7.76E-05 | 0 | 0 | 58.69405723 | 840.0151228 | IGHM;IGKC;IGLC3;IGLC2 |
| Vesicle-mediated transport Homo sapiens R-HSA-5653656 | 6/492 | 6.31E-05 | 0.00743 | 0 | 0 | 8.410428932 | 81.33626304 | IGKC;IGLC3;SAA1;IGLC2;IGHA1;IGHA2 |

| | | | | | | | | |
|---|--------|----------|---------|---|---|-------------|-------------|--|
| FCERI mediated Ca ²⁺ mobilization Homo sapiens R-HSA-2871809 | Mar-62 | 9.79E-05 | 0.0107 | 0 | 0 | 33.37041157 | 308.0737308 | IGKC;IGLC3;IGLC2 |
| Innate Immune System Homo sapiens R-HSA-168249 | 7/807 | 1.22E-04 | 0.0124 | 0 | 0 | 5.982139042 | 53.92865104 | IGHG3;IGHG4;IGHG2;IGKC;IGLC3;SAA1;IGLC2 |
| Immune System Homo sapiens R-HSA-168256 | 9/1547 | 2.34E-04 | 0.02236 | 0 | 0 | 4.012214966 | 33.54636585 | IGHG3;IGHM;IGHG4;IGHG2;IGKC;IGLC3;SAA1;IGLC2;LTF |
| Signaling by the B Cell Receptor (BCR) Homo sapiens R-HSA-983705 | 4/233 | 3.39E-04 | 0.03052 | 0 | 0 | 11.83957378 | 94.58824954 | IGHM;IGKC;IGLC3;IGLC2 |
| FCERI mediated NF-kB activation Homo sapiens R-HSA-2871837 | 3/111 | 5.47E-04 | 0.04652 | 0 | 0 | 18.63932898 | 139.9930224 | IGKC;IGLC3;IGLC2 |

| | | | | | | | | |
|--|--------|----------|---------|---|---|-------------|-------------|------------------|
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Homo sapiens R-HSA-198933 | 3/157 | 0.001493 | 0.1202 | 0 | 0 | 13.17812431 | 85.752336 | IGKC;IGLC3;IGLC2 |
| Role of LAT2/NTAL/LAB on calcium mobilization Homo sapiens R-HSA-2730905 | 3/162 | 0.001633 | 0.12492 | 0 | 0 | 12.77139208 | 81.9589089 | IGKC;IGLC3;IGLC2 |
| Amyloid fiber formation Homo sapiens R-HSA-977225 | Feb-68 | 0.004358 | 0.31753 | 0 | 0 | 20.28397566 | 110.2570502 | SAA1;LTF |
| Scavenging by Class B Receptors Homo sapiens R-HSA-3000471 | 05-Jan | 0.00723 | 0.50279 | 0 | 0 | 137.9310345 | 679.9401122 | SAA1 |
| FCERI mediated MAPK activation Homo sapiens R-HSA-2871796 | 3/289 | 0.008264 | 0.54975 | 0 | 0 | 7.159050233 | 34.33349591 | IGKC;IGLC3;IGLC2 |

| | | | | | | | | |
|---|--------|----------|---------|---|---|-------------|-------------|------------------|
| Formyl peptide receptors bind formyl peptides and many other ligands Homo sapiens R-HSA- | 08-Jan | 0.011543 | 0.73588 | 0 | 0 | 86.20689655 | 384.6257661 | SAA1 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production Homo sapiens R-HSA-3134963 | 13-Jan | 0.018692 | 1 | 0 | 0 | 53.05039788 | 211.1217133 | SAA1 |
| Advanced glycosylation endproduct receptor signaling Homo sapiens R-HSA-879415 | 13-Jan | 0.018692 | 1 | 0 | 0 | 53.05039788 | 211.1217133 | SAA1 |
| Fc epsilon receptor (FCER1) signaling Homo sapiens R-HSA-2454202 | 3/395 | 0.019101 | 1 | 0 | 0 | 5.237887385 | 20.73170498 | IGKC;IGLC3;IGLC2 |

| | | | | | | | | |
|--|--------|----------|---|---|---|-------------|-------------|-----------------------|
| Adaptive Immune System Homo sapiens R-HSA-1280218 | 4/762 | 0.023289 | 1 | 0 | 0 | 3.620237126 | 13.61128337 | IGHM;IGKC;IGLC3;IGLC2 |
| RIP-mediated NFkB activation via ZBP1 Homo sapiens R-HSA-1810476 | 21-Jan | 0.030027 | 1 | 0 | 0 | 32.8407225 | 115.128225 | SAA1 |
| TRAF6 mediated NF-kB activation Homo sapiens R-HSA-933542 | 24-Jan | 0.034245 | 1 | 0 | 0 | 28.73563218 | 96.96019099 | SAA1 |
| ZBP1(DAI) mediated induction of type I IFNs Homo sapiens R-HSA-1606322 | 26-Jan | 0.037047 | 1 | 0 | 0 | 26.52519894 | 87.41553486 | SAA1 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex Homo sapiens R-HSA-445989 | 26-Jan | 0.037047 | 1 | 0 | 0 | 26.52519894 | 87.41553486 | SAA1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-------------|-------------|------|
| ROS, RNS production in response to bacteria Homo sapiens R-HSA-1222556 | Jan-34 | 0.048177 | 1 | 0 | 0 | 20.28397566 | 61.51868449 | LTF |
| Cytosolic sensors of pathogen-associated DNA Homo sapiens R-HSA-1834949 | Jan-66 | 0.091468 | 1 | 0 | 0 | 10.44932079 | 24.99232926 | SAA1 |
| TRAF6 Mediated Induction of proinflammatory cytokines Homo sapiens R-HSA-168180 | Jan-72 | 0.099371 | 1 | 0 | 0 | 9.578544061 | 22.1158904 | SAA1 |
| RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Homo sapiens R-HSA-168928 | Jan-79 | 0.108506 | 1 | 0 | 0 | 8.729812309 | 19.3884414 | SAA1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-------------|-------------|------|
| Toll Like Receptor 10 (TLR10) Cascade Homo sapiens R-HSA-168142 | Jan-82 | 0.112394 | 1 | 0 | 0 | 8.410428932 | 18.38302695 | SAA1 |
| Toll Like Receptor 5 (TLR5) Cascade Homo sapiens R-HSA-168176 | Jan-82 | 0.112394 | 1 | 0 | 0 | 8.410428932 | 18.38302695 | SAA1 |
| MyD88 cascade initiated on plasma membrane Homo sapiens R-HSA-975871 | Jan-82 | 0.112394 | 1 | 0 | 0 | 8.410428932 | 18.38302695 | SAA1 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Homo sapiens R-HSA-975138 | Jan-83 | 0.113687 | 1 | 0 | 0 | 8.309098463 | 18.06655067 | SAA1 |
| MyD88 dependent cascade initiated on endosome Homo sapiens R-HSA-975155 | Jan-85 | 0.116266 | 1 | 0 | 0 | 8.113590264 | 17.45943983 | SAA1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-------------|-------------|------|
| Toll Like Receptor 7/8 (TLR7/8) Cascade Homo sapiens R-HSA-168181 | Jan-85 | 0.116266 | 1 | 0 | 0 | 8.113590264 | 17.45943983 | SAA1 |
| Toll Like Receptor 9 (TLR9) Cascade Homo sapiens R-HSA-168138 | Jan-88 | 0.120121 | 1 | 0 | 0 | 7.836990596 | 16.60858299 | SAA1 |
| MyD88:Mal cascade initiated on plasma membrane Homo sapiens R-HSA-166058 | Jan-92 | 0.125236 | 1 | 0 | 0 | 7.496251874 | 15.57387177 | SAA1 |
| Toll Like Receptor TLR1:TLR2 Cascade Homo sapiens R-HSA-168179 | Jan-92 | 0.125236 | 1 | 0 | 0 | 7.496251874 | 15.57387177 | SAA1 |
| Toll Like Receptor TLR6:TLR2 Cascade Homo sapiens R-HSA-168188 | Jan-92 | 0.125236 | 1 | 0 | 0 | 7.496251874 | 15.57387177 | SAA1 |

| | | | | | | | | |
|---|--------|----------|---|---|---|-------------|-------------|------|
| Toll Like Receptor 2 (TLR2) Cascade Homo sapiens R-HSA-181438 | Jan-92 | 0.125236 | 1 | 0 | 0 | 7.496251874 | 15.57387177 | SAA1 |
| MyD88-independent TLR3/TLR4 cascade Homo sapiens R-HSA-166166 | Jan-97 | 0.13159 | 1 | 0 | 0 | 7.109847138 | 14.41925158 | SAA1 |
| Toll Like Receptor 3 (TLR3) Cascade Homo sapiens R-HSA-168164 | Jan-97 | 0.13159 | 1 | 0 | 0 | 7.109847138 | 14.41925158 | SAA1 |
| TRIF-mediated TLR3/TLR4 signaling Homo sapiens R-HSA-937061 | Jan-97 | 0.13159 | 1 | 0 | 0 | 7.109847138 | 14.41925158 | SAA1 |
| Activated TLR4 signalling Homo sapiens R-HSA-166054 | 1/112 | 0.150384 | 1 | 0 | 0 | 6.157635468 | 11.66604345 | SAA1 |
| Toll Like Receptor 4 (TLR4) Cascade Homo sapiens R-HSA-166016 | 1/122 | 0.162694 | 1 | 0 | 0 | 5.652911249 | 10.265023 | SAA1 |

| | | | | | | | | |
|--|--------|----------|---|---|---|-------------|-------------|----------|
| Toll-Like Receptors Cascades Homo sapiens R-HSA- 168898 | 1/140 | 0.184421 | 1 | 0 | 0 | 4.926108374 | 8.327763361 | SAA1 |
| G alpha (q) signalling events Homo sapiens R-HSA- 416476 | 1/191 | 0.243064 | 1 | 0 | 0 | 3.610760065 | 5.107173062 | SAA1 |
| Peptide ligand-binding receptors Homo sapiens R-HSA- 375276 | 1/193 | 0.245278 | 1 | 0 | 0 | 3.573342862 | 5.021837388 | SAA1 |
| G alpha (i) signalling events Homo sapiens R-HSA- 418594 | 1/240 | 0.295559 | 1 | 0 | 0 | 2.873563218 | 3.502546682 | SAA1 |
| Class A/1 (Rhodopsin-like receptors) Homo sapiens R-HSA- 373076 | 1/323 | 0.376562 | 1 | 0 | 0 | 2.135155333 | 2.085348299 | SAA1 |
| Infectious disease Homo sapiens R-HSA- 5663205 | 1/348 | 0.399144 | 1 | 0 | 0 | 1.981767737 | 1.820119503 | LTF |
| Metabolism of proteins Homo sapiens R-HSA- 392499 | 2/1074 | 0.46633 | 1 | 0 | 0 | 1.284274064 | 0.979722471 | SAA1;LTF |

| | | | | | | | | |
|---|--------|----------|---|---|---|-------------|-------------|------|
| Gastrin-CREB signalling pathway via PKC and MAPK Homo sapiens R-HSA- 881907 | 1/432 | 0.469381 | 1 | 0 | 0 | 1.59642401 | 1.207439229 | SAA1 |
| GPCR ligand binding Homo sapiens R-HSA- 500792 | 1/447 | 0.48106 | 1 | 0 | 0 | 1.542852735 | 1.129004505 | SAA1 |
| Disease Homo sapiens R-HSA- 1643685 | 1/725 | 0.657519 | 1 | 0 | 0 | 0.951248514 | 0.398841023 | LTF |
| GPCR downstre am signaling Homo sapiens R-HSA- 388396 | 1/983 | 0.76837 | 1 | 0 | 0 | 0.701582068 | 0.184855213 | SAA1 |
| Signaling by GPCR Homo sapiens R-HSA- 372790 | 1/1293 | 0.856238 | 1 | 0 | 0 | 0.533376003 | 0.082783637 | SAA1 |
| Signal Transducti on Homo sapiens R-HSA- 162582 | Jan-65 | 0.978012 | 1 | 0 | 0 | 0.279778975 | 0.006220549 | SAA1 |

Data S2: Enrichment analysis for Biological Pathways using the tool Enrich.

Data S3

| | |
|---------------------|---|
| Data S3 | Correlations among PCs and selected clinical features of PRAD (TCGA, Cell 2015) |
| Tab Content: | |
| Tab 1 | Correlation between major clinical features of PRAD |
| Tab 2 | Correlation between major clinical features and PCs |

| Correlations | | | |
|---------------------|------------|-----------|------------|
| | erg | ar | cel |
| gleason | 0.02 | -0.09 | 0.26 |
| erg | | -0.24 | -0.06 |
| ar | | | 0.18 |
| | | | |
| P-values | | | |
| | erg | ar | cel |
| gleason | 0.73 | 0.11 | 0.00 |
| erg | | 0.00 | 0.31 |
| ar | | | 0.00 |

| Correlations | | | |
|---------------------|------------|------------|------------|
| | PC1 | PC2 | PC3 |
| gleason | 0.26 | -0.16 | 0.04 |
| erg | 0.02 | -0.18 | 0.24 |
| ar | 0.23 | 0.32 | 0.45 |
| cel | 0.37 | 0.14 | 0.19 |
| P-values | | | |
| | PC1 | PC2 | PC3 |
| gleason | 0.00 | 0.01 | 0.52 |
| erg | 0.66 | 0.00 | 0.00 |
| ar | 0.00 | 0.00 | 0.00 |
| cel | 0.00 | 0.02 | 0.00 |

Data S3: Correlations among PCs and selected clinical features of PRAD (TCGA, Cell 2015).